微信分享
VIF World 2024-第5届疫苗创新国际论坛

使用微信扫一扫分享到朋友圈

活动分享
VIF World 2024-第5届疫苗创新国际论坛

使用微信扫一扫进入小程序分享活动

活动详情

2024 第五届疫苗创新国际论坛(VIF World)即将在中国上海举办。 论坛将汇集来自世界各地的疫苗专家、研究人员、企业高层、政策制定者和行业领导者,共同推进疫苗开发和国际合作。由于世界面临新出现的传染性威胁和持续的健康挑战,在疫苗开发领域促进国际合作和知识交流至关重要。本次会议将作为分享前沿研究发现、讨论创新疫苗技术、解决全球免疫差距、促进公平疫苗分配的平台。


科学顾问委员会

1759044991808170.png

1759050541808170.png

VIF World 2024-第5届疫苗创新国际论坛

微信截图_20240120170928.png


往届回顾 1751038691808170.jpg1751034601808170.jpg

VIF World 2024-第5届疫苗创新国际论坛

VIF World 2024-第5届疫苗创新国际论坛

主要话题

  • 新型疫苗创新:

  • 传染病

  • RNA技术

  • 细菌疫苗

  • 动物疫苗

  • 癌症疫苗和免疫疗法

  • 生物加工与制造

  • 临床试验/疫苗安全性

  • 市场准入/监管/国际合作

  • 佐剂、配方和递送技术


壁报展示

1815534331808170.png


1对1会面系统

1815539341808170.png




活动嘉宾
  • Adjunct Professor of Medicine, Johns Hopkins Medical School Visiting Researcher, Institute of Microbiology, Chinese Academy of Sciences President, Siber Biotechnologies LLCGeorge Siber
    George Siber
    Adjunct Professor of Medicine, Johns Hopkins Medical School Visiting Researcher, Institute of Microbiology, Chinese Academy of Sciences President, Siber Biotechnologies LLC

    Dr. Siber is an infectious disease trained physician with more than 40 years of experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer) where he led the development and approval of multiple innovative childhood vaccines, including Prevenar 7 and 13, the first pneumococcal conjugate vaccines,  Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute and Director of the Massachusetts Public Health Biologic Laboratories where he developed multiple vaccines and immune globulins, including Respigam, the first antibody licensed for respiratory syncytial virus. Dr. Siber most recently was a Co-founder and Board Member of Affinivax which developed a 24 valent pneumococcal vaccine and was acquired by GSK in 2022. Dr. Siber currently serves on the Scientific Advisory Boards of AdVaccine, CanSino, Clover, Everest Medicines, ILiAD, Valneva, Vaxart and Vaxxinity and has been a consultant to the NIH, EU, WHO and the Gates Foundation. Dr.Siber was member of the Board of  Trustees of the International Vaccine Institute. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post‑doctoral training in Internal Medicine at Rush‑Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Boston Children’s Hospital and Beth Israel Hospital, Harvard Medical School.


  • CEO, DCVMN International, IndiaRajinder Suri
    Rajinder Suri
    CEO, DCVMN International, India
    Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN. Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.
  • CEO, Afrigen Biologics, South AfricaPetro Terblanche
    Petro Terblanche
    CEO, Afrigen Biologics, South Africa
    Professor Petro Terblanche has a successful track record in the strategic and operational management of technology intensive organizations. She has played a key part in the design and implementation of South Africa’s biotechnology strategy. She holds the position of Chief Executive Officer of Afrigen Biologics (Pty)Ltd based in Cape Town, South Africa. Afrigen hosts the WHO Global mRNA technology development and transfer Hub and has a mRNA Covid 19 vaccine candidate in development as part of a global program to build capacity and capabilities in LMICs to design, develop and produce mRNA vaccines. Prof Terblanche is the author of more than 200 scientific publications and conference papers in public health. Petro holds several Board positions and serves on a number of scientific advisory boards in the public health sector. She was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.
  • Professor, The Pirbright Institute, UKSimon Graham
    Simon Graham
    Professor, The Pirbright Institute, UK
    I am a veterinary immunologist with an interest in understanding mechanisms of protective immunity and its application to vaccine development. My early career focussed on parasitic diseases, I developed a natural cattle model for testing vaccines against onchocerciasis (river blindness), which provided the first proof-of-principle for vaccine-induced protection. I identified and evaluated vaccine candidate antigens from the apicomplexan parasite Theileria parva, which were designed to induce protective bovine CD8 T cell responses. More recently, my research has focussed on porcine viruses, such as classical swine fever (CSFV) and porcine reproductive and respiratory syndrome (PRRSV) viruses. I informed discussions on the use of emergency vaccination to control future CSF outbreaks by demonstrating that live attenuated CSFV prevented transmission of divergent CSFV strains after only 3 days. I showed that this rapid protection was associated with broadly reactive CD8 T cell responses, opening new avenues to develop DIVA vaccines for outbreak settings. For PRRSV, I contributed to the study of the enhanced pathogenicity of Eastern European strains, highlighting the threat these viruses pose; and contributed to vaccine development efforts through the identification of conserved T cell antigens. My current research is largely focussed on PRRSV and we are pursuing complimentary approaches to improved vaccine development. I am also leading research aimed at developing a Nipah virus vaccine for pigs and supporting COVID-19 vaccine development by using the pig as a preclinical model for assessing immunogenicity of vaccine candidates.
  • , CSO, GeneOne Life Science, USAKar Muthumani
    Kar Muthumani
    , CSO, GeneOne Life Science, USA
    Dr. Muthumani has been working on basic immunology and translational science, especially in vaccine and immunotherapy areas. He completed his MS and Ph.D. at the Madurai Kamaraj University and post-doctoral fellowship at the Perlman School of Medicine at the University of Pennsylvania, PA, USA, focused on viral pathogenesis, nucleic acid vaccines, and immune therapies. He has directed a translational research laboratory focusing on synthetic nucleic acid technology to develop novel vaccines and immunotherapies for emerging and reemerging infectious diseases at The Wistar Institute, PA-USA, as part of preclinical studies using small animals and non-human primates and facilitated the translation of several vaccine candidates into the human clinical trials. In addition, he was associated with, as an investigator or co-investigator, several grants, including the prestigious NIH-HVDDT program grant for HIV-1 vaccine development, a highly selective NIH directors translational grant for universal influenza vaccine development, Sponsored Research Agreement grant for studying the virus and host receptor interactions (Dengue, MAYV, POWV, and CHIKV), Defense Advanced Research Projects Agency (DARPA), WW Smith grant, and Emerson Collective Cancer Research grant regarding immunotherapeutics. Over the years, his laboratory developed, evaluated, and demonstrated the efficacy of vaccine immunogens for Human immunodeficiency virus (HIV), Chikungunya Virus (CHIKV), and Middle East Respiratory Syndrome (MERS), ZIKA, Nipah, POWV, MAYV, and SARS-CoV2 virus. Notable was that the synthetic nucleic acid vaccines MERS- Coronavirus (NCT03721718), Zika virus (NCT02887482), and SARS-CoV-2 (NCT04336410) were the first vaccines into human clinical testing. As a significant contributor to the vaccine literature, he has published 128 highly cited peer-reviewed scientific articles and book chapters, with a Google H-index of 39. In addition, the research articles appeared in scholarly journals, awarded 22 patents, and filed 25 patents (total of 47) for the work. Given his stellar scientific background and accomplishments, Dr. Muthumani is uniquely positioned to lead and tackle new challenges for emerging and reemerging diseases of public health importance or relevance.
  • Emeritus Professor, University of Massachusetts Medical School, USAShan Lu
    Shan Lu
    Emeritus Professor, University of Massachusetts Medical School, USA
  • Professor, Chonnam National University Medical School, South KoreaJoon Haeng Rhee
    Joon Haeng Rhee
    Professor, Chonnam National University Medical School, South Korea
    Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.
  • Founder, Vaxine, AustraliaNikolai Petrovsky
    Nikolai Petrovsky
    Founder, Vaxine, Australia
    Professor Nikolai Petrovsky is a physician and vaccine researcher. He is the founder of Vaxine, an Australian biotechnology company applying novel approaches including artificial intelligence to vaccine and adjuvant development. His research has been awarded multi-million dollar contracts from the US National Institutes of Health and he has authored over 200 peer-reviewed research papers. He developed SpikoGen®, a vaccine against COVID-19 that received emergency use authorization in the Middle East in October 2021, making it the first recombinant protein vaccine against COVID-19 to achieve regulatory approval.
  • President of Global Business, SK Bioscience, South KoreaHun Kim
    Hun Kim
    President of Global Business, SK Bioscience, South Korea
  • BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, ChinaAndrew Wong
    Andrew Wong
    BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, China
    Andrew Wong is Director of Business Development at Walvax Biotechnology Co., Ltd., a public listed company in China, and the general manager of its subsidiary Shanghai Wotai Biotechnology Co., Ltd.. Andrew is responsible for managing Global Registration and Sales Department and Business Development Department at Walvax. By participating in Walvax’s efforts to become a global vaccine manufacturer, between September 2015 and March 2020, Andrew managed a three collaboration projects under a combined sum of $8.5 million funding from the Bill and Melinda Gates Foundation to support the development of bivalent, nona-valent HPV vaccines and recombinant COVID-19 vaccine for developing countries. Representing Walvax, Andrew participated in the efforts with Shanghai Zerun to secure 3 grants from CEPI to support the preclinical and clinical development of the variant recombinant COVID-19 vaccines for eventual supply to COVAX. Currently, Andrew leads his teams to work on Walvax’s global business expansion through licensing-in/out and international product registration and distribution. After academic trainings from China, Canada and United States in clinical medicine, immunology, molecular biology, and business administration with an MBA from UCLA Anderson School, Andrew Wong, MD, MBA has almost three decades’ experiences in biopharmaceutical research, business development and general management, including close to 12 years’ work experience at the world’s largest biotech company - Amgen Inc. in USA, by engaging in recombinant antibody therapeutics and anticancer small molecule drug research and development.
  • Chief Science Advisor, Africa Centres for Disease Control and Prevention, EthiopiaNicaise Ndembi
    Nicaise Ndembi
    Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
    Dr. Nicaise Ndembi is Senior strategic Advisor on Sciece and Policy to the Africa Centres for Disease Control and Prevention Director General and currently Associate Professor, Division of Epidemiology and Prevention at the Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, USA. Dr. Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Public Health, Japan and a Research Professor within the same Institution. He is a Principal Investigator on numerous grants including US National Health Institute (NIH). He has authored/co-authored more than 180 publications in peer-reviewed journals. He is the Editor-in-Chief of the Journal of Public Health in Africa (JPHIA), AIDS Research and Therapy (ARTY), and serves on various WHO and US NIH Advisory Groups.
  • President, TechImmune, USAJeffrey Ulmer
    Jeffrey Ulmer
    President, TechImmune, USA
    Jeffrey B. Ulmer, Ph.D. spent more than 30 years in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis and GlaxoSmithKline. His most recent leadership positions included Global Head, External R&D; Head, Preclinical R&D; and Program Head, Technical R&D. His scientific focus has been vaccine technology platforms, including DNA and mRNA vaccines, viral vectors and adjuvants. He received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. He has published over 210 scientific articles, is an inventor on 11 patents, and is a Fellow of the International Society of Vaccines where he serves as Treasurer. He is currently President, TechImmune LLC (Newport Beach, CA) and Chief Scientific Advisor, Immorna Biotherapeutics (Morrisville, NC).
  • Scientific Director at PATH, USAKutub Mahmood
    Kutub Mahmood
    Scientific Director at PATH, USA
    Senior biotech executive professional with expertise in viral vaccines with 30yrs experience in vaccine development. Currently at PATH, leading projects for vaccines and biologics including product development strategies for compliance with GMP and/or GLP practices as applicable for national and international regulatory framework compliance (WHO, FDA, EMA,DCGI, NMPA). Experience in national regulatory approvals and for achieving WHO pre-qualification for vaccine products. Currently project lead for polio vaccines development and scaleup for OPV and IPV related work. Current and past projects at PATH includes work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. Holds national and international patents on VLP technology for influenza and RSV vaccines, and published in peer-reviewed journals. Presently serves as scientific advisory panel for companies and on several scientific panels for national and international vaccine meetings. Besides, serves as scientific reviewer for manuscripts submitted for publications in journals including Vaccine, Journal of Infectious Diseases, Emerging Infectious Diseases, and Human Vaccines & Therapeutics.
  • Professor, Trinity College Dublin, IrelandEd Lavelle
    Ed Lavelle
    Professor, Trinity College Dublin, Ireland
    Professor Ed Lavelle is the current Professor of Vaccine Immunology in Trinity College Dublin He was elected a member of the Royal Irish Academy (MRIA) in 2021 is currently President of ECI2024 and former President of the Irish Society for Immunology and head of the School of Biochemistry and Immunology at Trinity College Dublin, Ireland. He graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth and carried out postdoctoral research at the University of Nottingham, Rowett Research Institute, Maynooth University and Trinity College Dublin on vaccine adjuvants and immunomodulation. He was appointed at Trinity College Dublin as a lecturer in 2004, associate Professor in 2012, Professor in Immunology in 2015 and Professor of Vaccine Immunology in 2022. His research has led to the development of adjuvants suitable for inclusion in injectable and mucosal vaccines for infectious diseases and resolving their mode of action. The lab is also focused on developing therapeutic vaccines for cancer and investigating vaccine strategies that promote immunogenic cell death, leading to enhanced protective immunity.
  • Senior Advisor, Xiamen Innovax Biotech, ChinaJames Wai Kuo Shih
    James Wai Kuo Shih
    Senior Advisor, Xiamen Innovax Biotech, China
    James W. Shih is a senior advisor at the Innovax Biotech Inc. Xiamen, China and Professor Emeritus of the School of Public Health, Xiamen University, China since 2016. For over 10 years, he was Professor of Microbiology at the National Institute of Diagnostics and Vaccine Development in infectious diseases at the Xiamen University. He retired from the National Institutes of Health, Bethesda, USA in 2006. While at NIH, he was a senior investigator and served as the Chief of Lab Study, Infectious Disease Section and Supervisor of the Transmission Transmitted Virus Lab at the Department of Transfusion Medicine, NIH Clinical Center. Prof. Shih is a microbiologist with over 40 years of experience in the biomedical field. Most of his career is associated with the development and the understanding of hepatitis viruses and their clinical implications. He has managed active research programs in viral discovery and the development and evaluation of vaccines against hepatitis B and hepatitis C. He has extensive experience in development and clinical evaluation of serological and molecular diagnostics in infectious diseases. Currently, he is engaging in developing international collaborative projects one of them is the evaluation of hepatitis E vaccine.
  • Professor, Army Medical University, ChinaHaibo Li
    Haibo Li
    Professor, Army Medical University, China
    Dr. Haibo Li is a professor in the National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, Army Medical University (Third Military Medical University). He obtained his PhD in biological technology from Third Military Medical University in 2013. His current research activities focus on integrating chemical synthesis and immunology to discover novel mucosal vaccine adjuvants. He developed an original strategy to rationally design novel lipopeptides as mucosal adjuvants by mimicking the active sites of the bacterial lipoproteins. Dr. Li has published over 50 peer-reviewed papers and several books and book chapters. Now he is a council member of Chongqing Pharmacological Society.
  • Director, International Vaccine Design Center, Professor, University of Tokyo, JapanKen Ishii
    Ken Ishii
    Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
  • R&D Director, Advagene, ChinaMingi Chang
    Mingi Chang
    R&D Director, Advagene, China
    • Director of Research and Development, Advagene Biopharmaceuticals Inc • Director of Biologics Division, RuenHuei Biopharmaceuticals Inc. • Research Fellow, Protein Drug Project, Development Center for Biotechnology (DCB). • Assistant Professor. Section of Immunology, Department of Medicine, Tzu Chi University
  • CSO, Reber Genetics, ChinaFrank Chang
    Frank Chang
    CSO, Reber Genetics, China

    Dr. Frank Chia-Jung Chang obtains his Ph.D. from Life Science and Institute of Genome Science department of Taiwan Yang-Ming Medical University in 2012. He received his postdoctoral training at Molecular Biology Institute of Academia Sinica (Taiwan) and worked as visiting scholar in Frances H. Arnold’s laboratory (Nobel Prize in Chemistry winner in 2018), Chemical Engineering Department of Caltech (U.S.). He joined Reber Genetics as the supervisor of R&D Division in 2014. From 2017, Frank also works for business development and strategic layout of vaccine products (technology included).

     

    Dr. Chang has considerable expertise in virology, microbiology, reverse vaccinology and protein engineering for industrial production. His group has successfully developed novel subunit vaccines of swine PRRSV, pan-PCV, Mycoplasma, CSFV and PEDV in Reber Genetics, furthermore, also support the study of safe vector vaccine against ASF with external partners.


  • Professor, Fudan University, ChinaShibo Jiang
    Shibo Jiang
    Professor, Fudan University, China
    Dr. Shibo Jiang is a Professor at the Shanghai Institute of Infectious Disease and Biosecurity of Fudan University, Shanghai, China. His main research interest is the development of antiviral drugs and vaccines. He has published 572 papers (total IF: 7,662, average IF: 13.4) in SCI journals such as Cell (x3), Nature (x2), Science (x2), Lancet (x4), CNS’ sister journals (x71), with total 45,327 citations and an h-index of 105. He has applied for 104 patents, 54 of which were issued, and 11 of them were licensed out with 3 classes of innovative drugs and medical products used in clinics.
  • Head, External R&D Asia Pacific, Global R&D, Sanofi Pasteur, ChinaSean Du
    Sean Du
    Head, External R&D Asia Pacific, Global R&D, Sanofi Pasteur, China
  • Lecturer, University of Sheffield, UKZoltan Kis
    Zoltan Kis
    Lecturer, University of Sheffield, UK
    Dr. Zoltán Kis is a Lecturer at the Department of Chemical and Biological Engineering at The University of Sheffield, and an Honorary Lecturer at the Department of Chemical Engineering, Imperial College London. Zoltán is leading a multidisciplinary team that is innovating and digitalising RNA vaccine and therapeutics production platform technologies. His work is addressing the challenges of producing large volumes of RNA-based vaccines and therapeutics, rapidly, at high quality and at low cost in a disease-agnostic manner. Zoltán has previously worked as a Research Associate in the Future Vaccine Manufacturing Hub at Imperial College London. He obtained his Ph.D. in Bioengineering from Imperial College London, UK, holds an M.Sc. in Applied Biotechnology and a B.Eng. in Chemical with Biochemical Engineering.
  • CSO, Cansino Bio, ChinaTao Zhu
    Tao Zhu
    CSO, Cansino Bio, China

    Dr. Tao Zhu, Ph.D. the University of Pittsburgh

    Co-founder and Chief Scientific Officer of CanSino Biologics Inc. 


    Dr. Zhu is a member of the 14th National Committee of the Chinese People's Political Consultative Conference (CPPCC) and the “Healthy China Construction” professional committee of the Chinese Peasants and Workers Democratic Party. 


    Dr. Zhu focuses on the research and development of biological products. He established multiple core technology platforms, including viral vector, polysaccharide protein conjugate vaccine, VLP recombinant vaccine and mRNA vaccine technology at CanSino. Multiple projects led by him have been selected as national “Major Science and Technology Projects for New Drug Creation” and “Major Science and Technology Projects for Infectious Diseases”. 


    Dr. Zhu has led the team to develop a series of vaccine products, of which 6 vaccine products have been registered and marketed, another 7 vaccine products are in different stages of clinical studies. He co-developed the adenovirus vector-based Ebola virus vaccine (2018), the Recombinant COVID-19 Vaccine (Convidecia, 2021), the Recombinant COVID-19 Vaccine for Inhalation(Convidecia Air, 2022), and the Recombinant COVID-19 XBB Vaccine for Inhalation(2023), with the team of Academician Chen Wei of the Institute of Bioengineering, Academy of Military Medical Sciences, all of which have been marketed. Especially, Convidecia Air is the first developed inhalation vaccine product in the global. Menhycia, which was approved in 2021, is currently the only quadrivalent meningococcal conjugate vaccine on the market in China. Dr. Zhu also holds over 50 patents and 70 publications, including 15 papers from The Lancet publishers.


  • Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USAMichel De Wilde
    Michel De Wilde
    Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USA

    Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community and is member of several Scientific Advisory Boards

    From  2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at sanofi pasteur where he drove the development and licensure  of a number of products.

     

    From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine.

     


  • Associate Director, RA, MSDZhizheng Hu
    Zhizheng Hu
    Associate Director, RA, MSD
  • Research Associate, Cardiff University, UKMaria Dul
    Maria Dul
    Research Associate, Cardiff University, UK
    Maria, a chemist by training (MSc from Jagiellonian University in Krakow, Poland), completed her PhD in the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, working on ‘Engineering an oral delivery system for insulin’. She then moved to Cardiff University and in the last decade her research has predominantly focused on the development of innovative microneedle-based technologies for the delivery of small molecules, peptides, proteins and nucleic acids into the skin. Maria has extensive experience in the microneedle field, having used a range of microneedle prototypes in both pre-clinical and clinical projects. She is currently lead researcher in an international collaboration between key stakeholders (Microneedle Array Patch (MAP) Regulatory Working Group), which aims to advance the regulatory science of microneedle-based dosage forms by informing future guidance and developing standardized test methods for proposed MAP products.
  • Head of Process Development, Quantoom, BelgiumHela Kallel
    Hela Kallel
    Head of Process Development, Quantoom, Belgium
    Hela Kallel worked for more than 20 years at Institute Pasteur de Tunis in Tunisia; she was leading the bioprocess development lab. She worked on process improvement and on the development of vaccines using mainly animal cells and yeasts. In Jan 2020, Hela joined Univercells as a vaccine process development manager. She led the Measles and hepatitis A vaccines projects. In Jan 2022, she moved to mRNA technology and was appointed as the head of Process Development at Quantoom Biosciences. Recently She was nominated as the Head of Co-Development Projects at Univercells. Hela holds a Ph.D in biotechnology obtained at INPL in France.
  • CEO, AstriVax, BelgiumHanne Callewaer
    Hanne Callewaer
    CEO, AstriVax, Belgium

    July 2022 - current : AstriVax

    CEO and Co-founder


    July 2021 – July 2022: KU Leuven

    Entrepreneur in Residence


    June 2018 – August 2022: Oxurion

    Head Regulatory Affairs

    Business Development

    Chief Operating Officer


    March 2009 – May 2018: GSK Vaccines

    Regulatory Affairs

    Vaccine Development Leader


    Sept 2008 – Feb 2009 – Gevers Patents

    Trainee patent attorney


    About

    Diverse experience in the life science industry exhibiting a unique capability to merge operational execution and strategic development - implementation. Global industry experience in large pharmaceutical industry as well as into smaller biotech environment. Strong experience in development of commercial, late or early stage vaccines, monoclonal antibodies, peptides and small molecules. Regulatory affairs, drug and vaccine development expertise blended with business and corporate development. Proven track record to build up and lead diverse teams. Innovative mindset, with demonstrated ability to think beyond commonly accepted boundaries, understanding well different personalities and able to perform complex and challenging tasks and capable to distil the essence from the noise.


  • CSO, Delonix Bioworks, ChinaRong Xu
    Rong Xu
    CSO, Delonix Bioworks, China

    Dr. Xu Rong has over 20 years of experience in innovative vaccine research and development and in leading vaccine R&D teams within multinational corporations. She particularly excels in preclinical vaccine research and evaluation, the development and validation of immunological methodologies, and the CMC development of vaccine products.

     

    Before joining Delonix, Dr. Xu held the position of Senior Vice President of Preclinical Vaccine R&D at Clover Biopharmaceuticals. Prior to that, she served as the Vice President of R&D at the Sabin Vaccine Institute in the United States, where she led the CMC development, clinical immunology assay development and validation, and non-clinical safety and efficacy studies of vaccines. Additionally, she has held several key vaccine R&D and team management roles at Profectus Biosciences, Pfizer (Wyeth), and the Seattle Biomedical Research Institute.

     

    In 2016, Dr. Xu was honored with the Distinguished Female Scientist Award by the Westchester Association in New York, recognizing her outstanding contributions to vaccine research and development. Dr. Xu holds a Bachelor degree in Medicine from Peking University and a Ph.D. in Immunology from the Weizmann Institute of Science in Israel.


  • Professor, Army Medical University, ChinaQuanming Zou
    Quanming Zou
    Professor, Army Medical University, China
    Quanming Zou Professor & Director National Engineering Research Center of Immunological Products, Army Medical University Dr. Quanming Zou is a professor and the director of National Engineering Research Center of Immunological Products, Army Medical University. He received his PhD degree in immunology from the Third Military Medical University and research experience in University of Hannover (GER). He serves as Member of Subjects Review Group of the Academic Degrees Committee, State Council, Member of the 12th Pharmacopoeia Commission of China, Vice director of Biochemical and Biotech Medicine Professional Committee of Chinese Pharmaceutical Association, Vice director of Vaccine Research and Development Committee of the China Association for Vaccines and Vice Chairman of Chongqing Pharmaceutical Association. Dr. Zou has engaged in researches on innovative vaccines and pathogenic mechanisms and immune response of serious resistant bacteria. Prof. Zou successfully developed the Oral Recombinant Helicobacter Pylori Vaccine, which was approved with national innovative drug license. The other novel Staphylococcus Aureus Vaccine directed by Prof. Zou, have conducted the Clinical Trial phase Ⅲ. He published over 150 papers in peer-reviewed journals such as Lancet, Gastroenterology, Gut, Nature Communication,Autophagy, J Immunol, etc., and got 32 patents granted as first inventor. He won the Second prize of National Award for Technological Invention by the State Council, Outstanding Contribution to the Science and Technology Program Award by Ministry of Science and Technology, Frist prize of Chongqing Science and Technology Invention Award, Frist prize of Chongqing Natural Science Award by Chongqing Municipal People's Government, and Merit Citation Class II.
  • Professor,IMBCAM, ChinaQihan Li
    Qihan Li
    Professor,IMBCAM, China
  • CSO, CNBG-Virogin, CanadaWilliam Jia
    William Jia
    CSO, CNBG-Virogin, Canada

    Biography :

    n  Senior Scientist, Brain Research Centre, University of British Columbia (UBC), Canada (09.1994-07.2019)

    n  Associate Professor of Neurosurgery, UBC (tenured) (09.1994-07.2019)

    n  Chief Scientific Officer, Co-founder of Virogin Biotech Ltd (05.2015- present)

    n  Chief Scientific Officer, CNBG-Virogin Biotech Ltd (2019- present)

     

    Dr. Jia obtained his PhD in neurobiology from University of British Columbia (1991), MSc. Psychology (1987) from Dalhousie University in Canada, and BSc. Biology from Fudan University (1982) in China. In 2015, Dr.Jia co-founded Virogin Biotech, an oncolytic virotherapy company in Canada. He is currently the chief scientific officer of Virogin and CNBG-Virogin to develop oncolytic viruses and novel vaccines.


  • Deputy Department Head, Jiangsu CDC, ChinaJingxin Li
    Jingxin Li
    Deputy Department Head, Jiangsu CDC, China

    Jingxin Li, PhD, Professor, is working at Jiangsu Provincial Center for Disease Control and Prevention. Her research is focused on vaccine clinical evaluation and immunization strategy. She has participated in a lot of epidemiology investigations and a series of clinical trials of novel vaccines, including Enterovirus type 71 vaccine, recombinant human Ad5 vectored Ebola vaccine, and Covid-19 vaccines. She has got National Natural Science Outstanding Youth Founds and Jiangsu Provincial Natural Science Funds for Distinguished youths, and hosted or participated in seven National Natural Science Founds or National Science and Technology Major Projects. She has published over 25 articles in medical journals on vaccine clinical studies, including Nature Med, Lancet Respir Med, Lancet Glob Health, etc.


  • CEO/Co-founder, Cure Bio Tech, ChinaXia Jin
    Xia Jin
    CEO/Co-founder, Cure Bio Tech, China

    Xia JIN,MD, PhD is currently an executive director and Chief Executive Officer of Immuno Cure BioTech Ltd., Hong Kong. He has hold a number of academic positions previously, including Professor of Fudan University Shanghai Public Health Clinical Center, and its Director of Vaccine & Immunology Center; Distinguished Professor of the Chinese Academy of Science(CAS), and Deputy Director of Vaccine Research Center of the Institute Pasteur of Shanghai, and Deputy Director of CAS Molecular Virology & Immunology Key Lab. Before returning China, he has been a tenure-track Associate Professor of University of Rochester. His research focuses on the immune pathogenesis of human infectious diseases such as HIV and Dengue, and pre-clinical and clinical development of vaccines against these and other human pathogens.  He has published in 140 papers in peer-reviewed journals such as Science,J. Exp. Med.,J. Clin. Inv.,Nat. Commn., J Virol., Vaccine etc..

  • Assistant Professor, University of Pennsylvania , USAMohamad-Gabriel Alameh
    Mohamad-Gabriel Alameh
    Assistant Professor, University of Pennsylvania , USA

    Dr. Alameh is an Assistant Professor at Department of Pathology and Laboratory Medicine in the University of Pennsylvania and the Children Hospital of Philadelphia (CHOP), and the co-director of the Engineered mRNA and Targeted Nanomedicine Core at the Penn RNA Institute for RNA Innovation.

     

    Dr. Alameh obtained his Ph.D. in Biomedical Engineering in 2017 from Polytechnique Montreal under the supervision of Dr. Michael D. Buschmann and joined the laboratory of the now Nobel laureate Dr. Drew Weissman to develop multiple nucleoside-modified messenger RNA (mRNA) vaccines, study the adjuvant effect of different ionizable lipids, and develop new lipid-based delivery systems. Dr. Alameh explored the development of a novel lipid nanoparticle (LNPs) based adjuvant platform and developed potent mRNA-based vaccines against various pathogens including Clostridium difficile.

     

    His research program lies at the interface of nanotechnology, material science, engineering, and medicine to develop prophylactic and therapeutic nucleic acid-based delivery platforms and optimize their manufacturing. His team studies, and model Structure-Activity Relationships of material for improved delivery systems (e.g., lipid nanoparticle therapeutics), and nucleic acid-based vaccines. Their efforts are focused on dissecting the effect of different structural and physicochemical features of the delivery systems and their components (e.g., ionizable lipids, and helper lipids in lipid nanoparticles) on the performance, stability, and toxicity of these systems before and after interaction with the biological environment to develop vaccines against enteric pathogens, in utero and postnatal gene editing, and regenerative medicine.

     

    Current research projects include synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acid-based therapeutics (e.g., messenger RNA encoded base editors); development of mRNA-based vaccines against enteric pathogens, and the development of high-throughput screening platforms to assess material biocompatibility and toxicity.


  • Professor and Director  University of Karachi,  BangladashRaza Shah
    Raza Shah
    Professor and Director University of Karachi, Bangladash
    Prof. Shah is working in the area of Nanomedicines and clinical trials. He has authored six books (Elsevier) and also edited four books (Elsevier), along with 12 chapters in books and more than 460 research articles in international journals with impact factor more than 1700. He has several US patents to his credit too. He has supervised and co-supervised 34 Ph.Ds. and 44 M.S/M.Phil scholars. The research projects of Dr. Shah is funded by both National and International funding agencies. He was declared top scientist for the year 2019 by the government of Pakistan. He received the Civil award Tamgha-i-Imtiaz-2015 (Medal of Distinction) from President Islamic republic of Pakistan. Atta-ur-Rahman gold medal-2006 and Dr. Raziuddin gold medal-2015 by Pakistan Academy of Sciences. He received the Abdus Salam (Nobel Laureate) award, and was selected TWAS Young Affiliate in 2010 by The World Academy of Sciences. One of his authored books was declared best book of the year 2017 by Higher Education Commission of Pakistan. He is fellow Pakistan Academy of Sciences, fellow Islamic world academy of sciences, fellow International Union of Pure and Applied Chemistry (IUPAC), fellow the Chemical Society of Pakistan and fellow Royal College of Physicians Edinburgh. He remained a member in the panel of inspectors for Evaluation of Clinical Trial Sites from Drug Regulatory Authority of Pakistan (DRAP). He conducted 28 Phase-1 clinical-trials (BE-PK) along with 04 phase-II clinical-trials for Multinational pharma as PI. He led the vaccine (COVID-19) phase-1 clinical trial of Sinopharm company in Pakistan. He led the DRAP approved clinical trial for the treatment of COVID-19 patients with traditional Chinese medicines. Various Research Projects Sponsored by International Funding Agencies such as OPCW (Organization for the Prohibition of Chemical Weapons Netherlands), COMSTEC-ISECO (Saudi Arabia), International Foundation for Science (Sweden), Third World Academy of Sciences (Italy), DTRA (USA) and European Commission National Funding like HEC and PSF
  • CEO, InThera, South KoreaDeog-Young Choi
    Deog-Young Choi
    CEO, InThera, South Korea
    2016.05 – Present InThera Inc. CEO 2010.01 – 2015.12 LG Life Sciences, Ltd Director of Vaccine Development & Business 2000.07– 2009.12 LG Life Sciences, Ltd. R&D Center Head of Research Team 1995.09 – 1999.12 State University of New York at Stony Brook Ph.D. in Biology
  • Vice president of Chengdu Olymvax Biopharmaceuticals Inc., Head of Olymvax R&D institutionFan Fan
    Fan Fan
    Vice president of Chengdu Olymvax Biopharmaceuticals Inc., Head of Olymvax R&D institution
    Fan fan has nearly ten years experience in the biological industry and has made remarkable achievements. In 2016, she completed the in-licensing of Class I new drugs from Griffith University in Australia, which is the first aligned biological drugs project between universities in Queensland and enterprises in China. In June 2020, she was identified as the urgently needed talents and high-end talents by Chengdu High-tech Zone. She also serves as the standing committee member of Supply Chain Management Branch of China Association for Vaccines and the member of Meningitis Prevention and Control Branch of China Association for Vaccines. In September 2020, she was awarded the Advanced Individual against the epidemic by Sichuan Provincial Working Committee of Jiusan Society, and made her due contribution to the fight against the epidemic. In June 2021, she was awarded the Golden Panda "Talent Award" of Chengdu High-tech Zone.
  • CEO, Chimigen, ChinaEric Yuenian Shi
    Eric Yuenian Shi
    CEO, Chimigen, China
    Over 35 years of experience in biomedical research and development specializing in cancer research and translational medicine. Prior to founding Chimigen Bio, Dr Shi was Co-founder/CEO of OncoVent, a clinical-stage biopharmaceutical company. OncoVent’s leading candidate, Oregovomab, is a First-in-Class cancer immunotherapeutic drug belonging to the therapeutic cancer vaccine, currently in the global phase III stage. He was Vice President of the Academy of Clinical Research and Translational Medicine in Jiangsu Province since 2011. He led 4 research projects sponsored by the China National Science Foundation and 1 cancer early diagnosis research sponsored by the National Key Technology R&D Program for the 12th Five-year Plan of China. Prior to that Dr Shi was a full Professor at Albert Einstein College of Medicine, New York, where he led 12 national research programs funded by the U.S. National Cancer Institute (NCI), U.S. Department of Defense (DOD), and American Cancer Society. Dr Shi received his doctorate degree in biochemistry in 1989 at Dartmouth Medical School. Upon graduation from Peking University School of Medicine in 1983, Dr Shi was admitted into CUSBEA (China-U.S. Biochemistry Examination Application), a very selective and competitive program leading to graduate study at Dartmouth.
  • Chief Development Officer, Vaccines,Arcturus Therapeutics, USAIgor Smolenov
    Igor Smolenov
    Chief Development Officer, Vaccines,Arcturus Therapeutics, USA

    Igor Smolenov is the Chief Development Officer of Arcturus Therapeutics. Dr. Smolenov is an infectious disease physician dedicated to the clinical development of novel vaccines, with a proven record of accomplishment in both small biotechnology and large pharmaceutical companies. He contributed to the successful development and licensure of several innovative vaccines.

    Before joining Arcturus, Dr. Smolenov was the Executive Vice President at Clover Pharmaceuticals, where he built a robust team able to rapidly generate pivotal clinical data leading to adjuvanted COVID-19 vaccine authorization. Prior to that, Dr Smolenov served as Therapeutic Area Head, leading the development of several seasonal influenza vaccines in Seqirus (CSL), and Head of Clinical Development in Moderna Therapeutics, leading the initiation of the first clinical trials of mRNA vaccines in humans. At Novartis Vaccines, Dr. Smolenov contributed to the development and global licensure of meningococcal vaccines (Menveo, Bexsero, and MenABCWY) and the overall commercial success of the meningococcal vaccines franchise.

    Igor Smolenov graduated from Volgograd State Medical University, Russia, and holds MD, Ph.D., and Doctor of Science (Habilitation) degrees from this university. Before starting his career in the industry, he passed multiple academic steps from junior researcher to professor and head of the Allergy/immunology department of the university. He is the author of more than 50 publications in peer-reviewed journals in clinical pharmacology and vaccine development.


  • Associate Professor,Tulane University, USAElizabeth Norton
    Elizabeth Norton
    Associate Professor,Tulane University, USA
    Dr. Elizabeth B. Norton is an immunologist with 20 years of experience in evaluating immunity, vaccines, and microbial infections. The focus of her research is on immunity, including drivers of diversity and therapeutic interventions. She has a public health and research background and is an Associate Professor in the Department of Microbiology & Immunology at Tulane University in New Orleans, Louisiana, USA. Dr. Norton began her training at the Centers for Disease Control in Atlanta, GA identifying correlates of sepsis in children and assisting in field studies in African hospitals. In her doctoral and post-doctoral programs, she evaluated innate immunomodulation and mucosal delivery techniques, the latter in the laboratory of Dr. John Clements at Tulane University. A focus of her lab’s research is using mucosal adjuvants derived from heat-labile toxin (e.g., dmLT) as a strategy to improve memory responses to vaccines. This has involved adjuvanted enterotoxigenic E. coli (ETEC), polio and tuberculosis vaccines sponsored by NIH and Gates Foundation. Recently, she is also pursuing novel dmLT adjuvant combinations for oral vaccination. The Norton lab has also pioneered a derivative intranasal adjuvant called LTA1 for Klebsiella pneumoniae, opioid, and influenza vaccines and is preparing for an NIH-sponsored clinical trial with the former. Part of this research involves correlates of protection from clinical trials with these adjuvants or licensed vaccines. Since the SARS-CoV-2 pandemic, her lab is also a key part of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) evaluating cellular and memory responses to SARS-CoV-2 or other infections and vaccinations in healthy adults or special populations.
  • Senior Scientiest, Virogin Biotech, ChinaJiang Xu
    Jiang Xu
    Senior Scientiest, Virogin Biotech, China
    Dr. Jiang Xu has served as a senior scientist at Virogin Biotech since 2021, leading the microfluidics group. Prior to this, he worked at Harvard Medical School as a postdoctoral and held a PI scientist position at Boston Molecules Inc. Dr. Xu earned his cotutelle Ph.D. in Physical Chemistry from the University of Bordeaux and Ph.D. in Chemical Engineering from the University of Waterloo. Dr. Xu is particularly passionate about the multidisciplinary research of fluid dynamics, soft matter, and biomedical engineering. He has contributed to reputable journals such as Nature Communications, Small, Physical Review Fluids, etc. Notably, his work has garnered recognition from a series of prestigious funding and awards, including Harvard Catalyst Fellowship (2021), European Erasmus Mundus Fellowship (2012, Ph.D.), NIH Rapid Acceleration of Diagnostics (RADx®) grant (2020, PI), and Shanghai Rising-Star program (2023, PI).
  • 嘉晨西海生物 中国区CSO刘元庆
    刘元庆
    嘉晨西海生物 中国区CSO
    刘元庆,1988年毕业于上海复旦大学医学院,曾任上海中山医院普外科医生。博士就读于比利时布鲁塞尔自由大学, 师从Patrick De Baetselier教授探索肿瘤微环境和肿瘤疫苗。2008年加入赛诺菲巴斯德从事肿瘤疫苗研发,2010-2021年在赛诺菲巴斯德法国研发总部,先后主导多个核心课题,涉及传染病疫苗、小儿疫苗、新佐剂等,并作为工业界专家参加欧盟创新医学共同体,对于创新疫苗慨念验证、临床申报、工业化发展具有丰富的经验。2021年加入嘉晨西海任CSO,旨在助力加快中国mRNA疫苗和药物的研发。
  • 瑞宙生物CEO祝先潮
    祝先潮
    瑞宙生物CEO
    祝先潮博士:上海瑞宙生物科技有限公司创始人兼总经理,专注于创新疫苗及重组蛋白类生物制品的研发及产业化。曾在国内外一流制药企业从事新药研发二十多年,主导或参与过二十多个新型疫苗及新药研发项目,在小分子药物、重组蛋白、抗体、及疫苗产品的开发积累了丰富的经验。其中,在美国辉瑞公司圣地亚哥研发中心从事新药研发工作近13年,担任首席研究员及蛋白科学部负责人。 2011年回国后,先后在华兰生物工程股份有限公司担任首席科学官,在美国药典委员会大中华区担任生物药和生物技术部负责人和高级总监。祝博士在美国加州大学获得分子生物学及生物化学博士学位,在中科院上海有机化学研究所获得有机化学硕士学位,在清华大学获得化学系学士学位。
  • Director of Chula Vaccine Research Center, Chulalongkorn UniversityKiat Ruxrungtham
    Kiat Ruxrungtham
    Director of Chula Vaccine Research Center, Chulalongkorn University
    Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)
  • 三叶草生物研发总裁,英国Nicholas Jackson
    Nicholas Jackson
    三叶草生物研发总裁,英国
  • Lemonex首席技术官,韩国Dal-Hee Min
    Dal-Hee Min
    Lemonex首席技术官,韩国
    Dal-Hee Min is currently co-founder & CTO of Lemonex and Professor at Seoul National University. She received her Ph.D in Chemistry from University of Chicago. After post-doctoral research at MIT, she started her academic carrier at KAIST (Korea) as an Assistant Professor in 2007 and moved to Seoul National University in 2011. Her research focuses on drug delivery systems with collective understanding on nano-surface chemistry and diverse biomedical applications of nanomaterials including mRNA vaccines and gene therapies. She received various prestigious awards including ‘KCS-Wiley Young Chemist Award’, ‘Korea L’Oreal UNESCO Fellowship Award for Women in Science’ and ‘Order of Science and Technological Merit (Do-Yak Medal)’ from Korea Government. She is actively involved in many global activities. For highlighted activities, she gave two invited talks at World Economic Forum in 2018 where she introduced DegradaBALL technology-‘Miniaturizing Biotechnology’ in sessions ‘Bio-Inspired Drug Delivery’ and ‘Harnessing Nature for Technology ‘. She also gave talks about drug delivery platform technology at mRNA health conference, PODD, JP Morgan and BIO USA. Focus Area: mRNA vaccine / gene therapy / Nanobiotechnology / Nanomedicine/ Drug Delivery / Immunotherapy
  • Executive Vice President, The Wistar Institute, USADavid Weiner
    David Weiner
    Executive Vice President, The Wistar Institute, USA

    Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation (EP) technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study. His laboratory’s work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immunotherapy) in humans. Dr. Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immunotherapy. In 2019, Dr. Weiner was honored with the Scientific Achievement Award from Life Sciences PA (LSPA). Dr. Weiner returned to Wistar in 2016 from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine. Dr. Weiner is a co-founder of Inovio Pharmaceuticals and is a member of the Board of Directors. Dr. Weiner graduated with a B.S. in biology from SUNY at Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.

  • 四川大学研究员, 威斯津联合创始人/总经理宋相容
    宋相容
    四川大学研究员, 威斯津联合创始人/总经理

    宋相容,药剂学博士,生物学博士后,哈佛医学院纳米医学和免疫学访问教授,现为四川大学华西医院生物治疗全国重点实验室的研究员/博士生导师,入选国家级青年人才,国家重点研发计划首席科学家,威斯津生物联合创始人/总经理。

    从事基于靶向递送的创新药物研发近20年,聚焦mRNA创新药物研究10余年,突破了mRNA药物研发的关键底层技术,布局了mRNA序列、递送载体和智能制造设备等核心专利。

    主持国家重点研发计划、国家科技重大专项、国家自然科学基金等课题30余项,在Nat Comm、Sci Adv等发表一作/通讯SCI论文60余篇。

    申请发明专利73项(国际专利10项),已授权23项、实现企业转让4项;牵头转予药企的成果3项。

    主持的纳米佐剂(WGa01)已获紧急使用许可(EUA)上市、3个1类mRNA新药已经进入了临床试验。

    相关研究荣获:国家科技部2022年度全国颠覆性技术创新大赛优胜奖(最高奖,排名第1),任Sig Transduct Target Ther、Asian J Pharm Sci、Eur J Pharm Sci编委 、中国医药生物技术协会纳米生物技术分会委员、中国疫苗行业协会核酸疫苗分会委员、美中药协SAPA西部创新中心理事长等。


  • 广州实验室研究员陈凌
    陈凌
    广州实验室研究员

    Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.

  • 复旦大学附属公卫中心研究员鄢慧民
    鄢慧民
    复旦大学附属公卫中心研究员

    鄢慧民,博士,复旦大学上海市公共卫生临床中心,研究员,博士生导师。鄢博士毕业于武汉大学生物系,获学士、博士学位,并留校任教。1998-2002年在美国凯斯西保留地大学(Case Western Reserve University)医学院病理学系Research Associate,从事黏膜IgA抗病毒机制研究。2002年9月回国加盟武汉大学现代病毒学研究中心,参与武汉大学P3实验室SARS病毒科技攻关。2006年受聘中国科学院武汉病毒研究所,任研究员,学科组长(PI),组建黏膜免疫学科组。曾任研究所分子病毒研究室主任,病毒病理研究中心主任,研究所学位委员会副主任,湖北省免疫学会副理事长,湖北省微生物学会理事,中国病毒学(Virologica Sinica)杂志编委,中国国家知识产权局(State Intellectual Property Office of China)中国专利审查技术专家。他的实验室是中国病毒学国家重点实验室的成员单位。研究方向:黏膜免疫抗病毒机制及其应用。研究内容:病毒特异IgA抗体抗病毒机制,黏膜疫苗、黏膜佐剂与黏膜上皮细胞的相互作用及黏膜免疫效应,重组鞭毛素蛋白免疫识别机制及其在黏膜疫苗研发中的应用。2020年9月鄢博士受聘复旦大学上海市公共卫生临床中心,任黏膜免疫实验室PI,继续研究黏膜IgA抗病毒感染的功能,并更加关注病毒非表面和非结构成分特异IgA抗体在黏膜上皮细胞内地独特功能机制。相关研究证明了麻疹病毒(MV)非表面蛋白(基质蛋白M)、非结构蛋白(磷蛋白P)特异性IgA抗体可以在病毒感染的上皮细胞内转运过程中作用到病毒新合成的蛋白靶标,从而抑制病毒在黏膜上皮细胞内的复制。此外,他带领团队研发了基于TLR5的重组鞭毛蛋白黏膜佐,并应用于新型亚单位黏膜疫苗设计。相关研究获得鞭毛素蛋白佐剂、龋齿疫苗、RSV疫苗相关的美国专利3项、中国专利4项。这些研究得到了国家自然科学基金委、科技部的多个项目资助。


  • 迈科康生物董事长、总经理陈德祥
    陈德祥
    迈科康生物董事长、总经理
    陈德祥,迈科康生物董事长、总经理,密西西比州立大学免疫学博士,先后在辉瑞(Pfizer)、诺华(Novartis)和帕斯适宜(PATH) 科技组织从事疫苗和疫苗佐剂开发工作超30年,期间主持了多项由国际组织、基金会和国家政府资助的重大国际公共卫生专项课题。主持和参与的20多种传染病疫苗开发项目中,有多个产品在全球上市。陈德祥博士在科学(Science)和自然医学(Nature Medicine)等世界一流学术杂志上发表疫苗相关的学术论文60多篇。
  • 厦门大学教授李少伟
    李少伟
    厦门大学教授
    李少伟博士,厦门大学生命科学学院/公共卫生学院教授,国家传染病诊断试剂与疫苗工程技术研究中心疫苗组组长,福建省翔安创新实验室副主任。入选国家百千万人才工程、教育部新世纪优秀人才和《自然•生物技术》评选的2016年度全球转化研究TOP20(大陆学者首次入选),担任世界卫生组织疫苗产品开发咨询委员会(WHO-PDVAC)成员(20名成员中唯一中国学者)。作为核心研究人员研制全球首个戊肝疫苗、首个国产HPV疫苗和国内首个第三代艾滋诊断试剂等新药。主持国家863计划项目、新药创制国家科技重大专项、重点研发计划和国家自然科学基金等;获国家科技进步二等奖、国家技术发明二等奖、中国专利金奖、求是杰出科技成就集体奖和中国科协求是杰出青年成果转化奖等;在《细胞•宿主与微生物》《自然•微生物学》《自然•通讯》等发表SCI论文120余篇;获得发明专利授权29项。
  • 艾棣维欣首席科学家王宾
    王宾
    艾棣维欣首席科学家
    王宾 教授,, 艾棣维欣生物执行董事、董事会主席及首席科学家,复旦大学基础医学院特聘教授,中国疫苗行业协会核酸疫苗分会主任委员。王宾博士在疫苗研发领域拥有超过30年的经验。王宾博士在美国Wistar研究所和宾夕法尼亚大学医学院工作期间,和导师David Weiner教授最早发明了DNA疫苗技术。回国之后,王宾博士在创新疫苗领域,尤其是DNA疫苗以及创新佐剂方面有着深入的研究,累积发表150余篇SCI论文,获得超过40项国际发明专利,主持并参与了国家“863”重大项目、自然科学基金重点项目、 “十二五”重大新药创制、“十三五”国家传染病防治重大专项、“十四五”重点专项等重要科研课题。设计和参与了多项治疗性疫苗和预防性疫苗的临床试验。王宾博士也是Emerging Microbes & Infections及Human Vaccines & Immunotherapeutics等国际期刊的编委会成员。
  • CEO, Hilleman LaboratoriesRaman Rao
    Raman Rao
    CEO, Hilleman Laboratories

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


  • Prof., Northwest A&F UniversityXiaodong Xu
    Xiaodong Xu
    Prof., Northwest A&F University
    Xu Xiaodong, currently a professor and doctoral supervisor in the School of Life Sciences of Northwest A&F University, holds a master's degree in China Agricultural University and a doctor's degree in virology from the University of Reading, UK. He is mainly engaged in the research on the gene function and molecular biological mechanism of baculovirus, the optimization of baculovirus/insect cell expression system and the application and development of protein products. More than 10 domestic invention patents and 1 PCT international invention patent have been applied. In 2019, Xu Xiaodong led a team to discover prions in viruses for the first time in the world. The relevant scientific research results were published in the internationally renowned journal Nature Communications. Xu Xiaodong, as the founder of qBac® baculovirus/insect cell protein expression system, has improved the protein yield by the level of grams per liter by knocking out many genes that affect the protein yield, inserting siRNA to inhibit the apoptosis of host cells, and fine-tuning the expression level of transcription factors.
  • GM/CSO, Nano Microgene, ChinaEnqi Du
    Enqi Du
    GM/CSO, Nano Microgene, China
  • Application Engineer,NanoFCM INC.Huijie Zhu
    Huijie Zhu
    Application Engineer,NanoFCM INC.
    After graduating from the University of New South Wales,she has been responsible for the application development and pre-sales technical support of nano-flow cytometry, with solid theoretical foundation and rich experience in LNP characterization.
  • Chief Scientist, Shenzhen Institute of Advanced Technology, ChinaAldo Tagliabue
    Aldo Tagliabue
    Chief Scientist, Shenzhen Institute of Advanced Technology, China
    Aldo Tagliabue has been active for more than 4 decades in research, development, management, strategic planning and establishing facilities for innovative vaccines. After a long career as experimental immunologist and as manager of large cooperation R&D projects in public-private partnerships funded by the European Commission, Aldo Tagliabue has been involved in the creation of start-up companies in the field of human vaccines, such as AchilleS Vaccines Srl, a company of the Siena Vaccine Hub (Italy), and BCGene in São Paulo (Brazil). He has recently founded Veterna Srl, to develop mRNA vaccines for veterinary infections. His scientific background is based on early experience in the public sector, including a postdoctoral period at the NCI/NIH in Bethesda, MD, USA, from 1976 to 1979, and an internship at the McMaster University in Hamilton, Ontario, Canada in 1981. This was the basis for his subsequent experiences in industry. In 1982, he joined the Sclavo Research Center in Siena (Italy) as Head of Immunology, and in 1990 he became R&D Director at the pharmaceutical company Dompé in L’Aquila (Italy). In the early 2000s, he was Deputy Director at the International Vaccine Institute in Seoul (Republic of Korea), a WHO and UN initiative, and also served as a member of the Programme/Policy Committee of the GAVI Alliance Board. In 2011, with Rino Rappuoli he created the Sclavo Vaccine Foundation, whose mission is to sustain and promote vaccines for poverty related diseases. From 2014 to 2017, he was Director General of the Regional Foundation for Biomedical Research in Milan, the funding agency of the Lombardy Region (Italy) for health sciences. He was Adjunct Professor of Immunology at the University of Bologna (Italy) from 1996 to 2006, and Adjunct Professor at the Seoul National University from 2003 to 2005. He is author of more than 120 publications in immunology and vaccinology and inventor in 10 patents. Since 2017 is Senior Associated Scientist of the Italian National Research Council. In September 2021 he moved to China, at the Shenzhen Institute for Advanced Technology, as Visiting Professor supported by Chinese Academy of Science with a President International Fellowship. Recently he was awarded with a professorship in the Yangtze River Scholar Fellowship Program for his experience in vaccinology.
  • Distinguished Professor, Shenzhen Institute of Advanced Technology, ChinaDiana Boraschi
    Diana Boraschi
    Distinguished Professor, Shenzhen Institute of Advanced Technology, China
    Diana Boraschi is an immunologist that built her experience in academic institutions and industrial settings in her home country (Italy) and abroad (USA, France, Austria, Korea, Brazil). She is Senior Associate Researcher at the Italian National Research Council (where she served as Institute Director) and at the Stazione Zoologica Anton Dohrn in Napoli, Italy, and Academician of the Accademia dei Fisiocritici. She is currently serving as Distinguished Professor at the Department of Pharmacology at the Shenzhen Institute of Advanced Technologies (SIAT) of the Chinese Academy of Sciences, in Shenzhen, China. She is author of over 200 peer-reviewed research articles in immunology (h-index 67, over 16000 citations), in addition to many books and book chapters, and inventor in eight patents. In 2017, she has received an honorary PhD degree by the University of Salzburg (Austria), in 2020 the High-Level Talents Program Award for Foreign Scholars, and in 2022 the Chinese Government Friendship Award. She is listed within the first 2% scientists worldwide since 2017 and in the first 1% since 2020. Her area of expertise is innate immunity and inflammation, in particular in relation to autoimmune, inflammatory and degenerative diseases, and vaccine development. Her focus on macrophages and cytokines of the IL-1 superfamily (a bioactive IL-1 domain is known as the “Boraschi loop”), and the interaction of engineered nanomaterials with immunity in humans and environmental species. She is particularly involved in higher education training activities in Europe, Asia, Africa, and South America, with a focus on poverty-related diseases.
  • Co-founder& CSO, VisMederi, ItalyEmanuele Montomoli
    Emanuele Montomoli
    Co-founder& CSO, VisMederi, Italy
    Emanuele Montomoli was graduated in Life Sciences at University of Siena in 1997. Since November 2016 he was appointed by the Department of Molecular Medicine of University of Siena as full Professor on Public Health. Since April 2018 to 2021 he was nominated in the Executive Board of the Toscana Life Sciences Foundation. Since 2010 he he was elected as President of the Board for the “Master in vaccinology and drug development” at University of Siena. Since 2019 he was nominated in the Executive Board of Eurocine vaccines AB. In 2008 he funded VisMederi srl, an enterprise involved in laboratory activities for vaccines and antiviral drugs clinical trials. Actually, he has a role of Chief Scientific Officer in VisMederi srl. Since 1994 he has carried out epidemiological research, surveillance networks for infectious diseases and serological assays for clinical trials for vaccines. In 2015 he was appointed as scientific coordinator for a project funded by EU-IMI (Innovative Medicine Initiative) titled “Standardization and development of assays for assessment of influenza vaccine correlates of protection”. He is the author of more than 200 papers, as well as numerous abstracts and letters, published in international scientific journals.
  • VP, Innorna, ChinaZhangjing (Jim) Chen
    Zhangjing (Jim) Chen
    VP, Innorna, China
    Zhangjing Chen, VP, Clinical Science in Vaccine and Infectious disease, Innorna • Lead the development strategy and study execution for Innorna’s proprietary mRNA prophylactic vaccines since joining in 2022. • Sixteen-year journey in industry, concentrating in clinical development of anti-infective agents and prophylactic vaccines in Pfizer, Astrazeneca, Janssen and native biotech companies. • Lead or contribute to the development strategy, protocol generation, study execution, IND/CTA/BLA application, and post-marketing strategy in China for various vaccine products, including pneumococcal conjugated vaccine, COVID-19 vaccine, Respiratory Syncytial Virus vaccine, extra-intestinal pathogenic Escherichia coli vaccine. • Nine-year clinical practice in Infectious Disease in Huashan Hospital Fudan University and participated into international multi-center clinical trials or national registration clinical trials for several novel antimicrobials. • Master of Internal Medicine, Shanghai Medical College, Fudan University • Bachelor of Clinical Medicine, Shanghai Medical College, Fudan University
  • CEO, Stemirna, ChinaHangwen Li
    Hangwen Li
    CEO, Stemirna, China
    Dr. Hangwen Li holds a Ph.D from MD. Anderson Cancer Center. He was Assistant Professor at the Department of Pharmacology and Clinical Therapy of MD Anderson Cancer Center and successively received grants and awards from the US Department of Defense. He is currently a distinguished researcher of Dongfang Hospital of Tongji University, a member of the Vaccine International Cooperation Promotion Branch of the China Association For Vaccines, and a permanent member of the Nucleic Acid Vaccine Branch of the China Association For Vaccines. Dr. Li has more than 19 years of experience in the field of RNA and cancer immunotherapy. His research fields include tumor immunotherapy, RNA drugs and cancer stem cells. He has published more than 30 SCI articles and publications, and his articles have been cited for more than 3000 times. In 2021, he won the National Science and Technology System's award for Distinguished Individual in Fighting the Covid-19 Pandemic, and in 2022, he won the “Gold Gathering Award” in the Shanghai Global Talents Innovation & Entrepreneurship Competition. In 2016, Dr. Li returned to China and founded StemiRNA, which is the first company in Asia that focuses on the research and development of innovative mRNA drugs and vaccines. StemiRNA has now developed into a global leader and the first domestic platform innovative drug enterprise for mRNA vaccine and drug research and development in China. Its self-developed lipid polymer nano carrier (LPP) technology platform has been granted patents in Europe, America and other places. StemiRNA’s pipelines include mRNA vaccines and drugs for a series of infectious diseases (including COVID-19, influenza, etc.), tumors, and rare diseases.
  • Professor, Dalian University of Technology, ChinaBingbing Sun
    Bingbing Sun
    Professor, Dalian University of Technology, China
    Dr. Bingbing Sun received B.S. and M.S. in Chemical Engineering from Dalian University of Technology (DUT), and a Ph.D. in Chemical Engineering from the University of Washington. He had his postdoctoral training at the University of California's Center for Environmental Implications of Nanotechnology (UC-CEIN) at the University of California, Los Angeles (UCLA). He starts his academic career in the School of Chemical Engineering at DUT in 2016. Currently, he is a full professor and serves as the chair of the Department of Chemical Engineering at DUT. His research interest includes vaccine adjuvants, formulation, biomaterials, nano-bio interface, and immunoengineering. He serves as earlier career researchers editorial board of BMEMat.
  • Professor & Director, Jinan UniversityFeng Gao
    Feng Gao
    Professor & Director, Jinan University
    Dr. Feng Gao is a professor and director of the Institute of Molecular and Medical Virology at Jinan University. Dr. Gao has a long-standing interest in elucidating the origin, evolution and genetic variation of human and simian immunodeficiency viruses (HIV/SIV) as well as in studying gene function, pathogenesis and vaccines of HIV/SIV from the evolutionary perspective. He has published over 200 scientific research papers, including many in the top tier journals such as Cell, Nature and Science. He discovered that origin of HIV-1 in chimpanzees. He developed the consensus gene vaccine approach for induction of cross-subtype immune responses by reducing the distances between epidemic HIV-1 strains and vaccine immunogens. He also studied the coevolution of broadly neutralizing antibodies (bnAbs) and HIV-1 in the same infected host and discovered a cooperative mechanism between different bnAbs to drive maturation of the bnAb lineage. His publications have been cited over 31,000 times and his h-index is 83. Currently, his research mainly focuses on pathogenesis of viral infections, vaccines, transmission mechanisms, drug resistance, oncolytic viruses, ultra-sensitive detection and development of fetal immunity.
  • Professor, Lanzhou Veterinary Research Institute, ChinaHuichen Guo
    Huichen Guo
    Professor, Lanzhou Veterinary Research Institute, China

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


  • 阿普塔医药业务发展总监Nektaria Karavas
    Nektaria Karavas
    阿普塔医药业务发展总监
    Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America focusing on nasal drug delivery. She has contributed to multiple nasal development programs, supported commercial scale up and product launches for New Drug Applications (NDA) using an Aptar delivery device for key pharmaceutical clients across different therapeutic indications. Nektaria holds a Bachelor of Science from McGill University, Montreal, Canada
  • 阿普塔医药全球科学事务副总裁Julie D. Suman
    Julie D. Suman
    阿普塔医药全球科学事务副总裁
    Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce. She is a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001. In 2008, Dr. Suman received an award from the Greater Baltimore Committee for Entrepreneurial Spirit.
  • Co-founder& VP, TherarnaCaiyi Fei
    Caiyi Fei
    Co-founder& VP, Therarna
  • 中山大学教授陈永明
    陈永明
    中山大学教授
    Yongming Chen received his Ph.D. on polymer science in 1993 from Nankai University. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in University of Düsseldorf and University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013. He obtained “Distinguished Young Scholars” by National Science Foundation of China (2006). He served for Polymer, an Elsevier journal, as an Associate Editor during 2007 to 2018. He also was in Advisory Board Panel of Macromolecules and ACS Macro Letters, the ACS Publication. Professor Chen’s research interests are in the areas of biomaterials chemistry and biomaterials application in delivery of proteins and nucleic acids, specifically application in immune attenuation. He has published over 260 research articles in Science Advances, Nature Communication, Biomaterials, Nano Letters et al and obtained 10 more licenced patents. Contact: Email: chenym35@mail.sysu.edu.cn
  • President, Vaccine Division, Fosun PharmaJiguo Zhang
    Jiguo Zhang
    President, Vaccine Division, Fosun Pharma
    张继国先生担任复星医药疫苗事业部总裁,此前曾在多家跨国公司中国以及全球总部担任高管,也曾担任上市公司睿智医药CEO,在疫苗领域、并购整合、公司管理等方面积累了丰富经验。张继国先生以优异的成绩毕业于北京大学医学部以及北京大学国家发展研究院,毕业后曾留校任教。张继国先生也是虹博基因的联合创始人兼CEO,同时也是中国疫苗行业协会委员,中国大健康业务发展协会(CHBD)荣誉会长。
  • Professor, Tsinghua UniversityLinqi Zhang
    Linqi Zhang
    Professor, Tsinghua University
    Professor Linqi Zhang is the Director of the Comprehensive AIDS Research Center at Tsinghua University. Prof. Zhang's research focuses on HIV-1 pathogenesis and vaccine development, and has recently expanded to the field of emerging and re-emerging human viral pathogens such as SARS-CoV-1/2 and MERS-CoV. Using cutting-edge antibody and combinatorial antigen library techniques, Prof. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Professor Zhang is the recipient of the National Outstanding Young Scientist Award, privileged Changjiang Professorship, and Bayer and Vanke Chair professor. He has published extensively and is among the most cited Chinese researchers in the field of microbiology and immunology. Professor Zhang has also served as a member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases,and was recently elected as a Foreign Fellow of the African Academy of Sciences.
  • Professor, Shenzhen Institute of Advanced Technology, CASFan Yang
    Fan Yang
    Professor, Shenzhen Institute of Advanced Technology, CAS
    Dr. Fan Yang, professor at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. Dr. Yang earned her Ph.D. in Molecular Genetics and Computational Biology from the University of Toronto and conducted postdoctoral research at Stanford University. Her work primarily focuses on leveraging nulti-omics techniques and big data analysis algorithms to reveal the pathogenesis of diseases such as respiratory infections and autoimmune diseases, as well as the characteristics of related adaptive immune responses. Dr. Yang has published in Science, Cell, Nature Medicine, and Cell Host & Microbe and many other top articles, totaling over 4700 citations. She also acts as a peer reviewer for journals such as Genome Research, Frontiers in Oncology, PLoS Computational Biology, and Scientific Data, and served as an editor for Frontiers in Pharmacology, a Program Committee member and reviewer for ACM Special Interest Group on Computer Science Education (SIGCSE) conferences, and a committee member of the International Workshop on Computational Mathematical Models in Cancer (CMMCA).
  • Vice President, Suzhou HealiRNA BiotechnologyZhong Chen
    Zhong Chen
    Vice President, Suzhou HealiRNA Biotechnology
    Doctor of Pharmacy, Postdoctoral Fellow at UNC Chapel Hill, USA. During his academic career, he was awarded the title of Associated Professor. Presided over and/or participated in a number of National Natural Science Foundation projects and national Science and Technology major projects for new drug development, and participated in the successful marketing of small molecule innovative drugs. He has published 20 academic papers in international journals and authorized 10 Chinese invention patents. In the past 5 years, he has focused on the development and industrialization of nucleic acid drug delivery vectors (mRNA, siRNA) and nucleic acid medicinal chemistry, and has applied for a number of PCT patents. He has accumulated a lot of industrialization experience in nucleic acid drug project selection, delivery vector development and CMC research.
  • Prof., Jilin University;Senior Advisor, Scientific Advisor, ProMab Forethought; Scientific Advisor, Changchun BCTHChongyang Liang
    Chongyang Liang
    Prof., Jilin University;Senior Advisor, Scientific Advisor, ProMab Forethought; Scientific Advisor, Changchun BCTH
    Professor Liang is dedicated to the development of large molecular drugs in the field of recombinant protein. He has been engaged in the research of drug action mechanism-related structural biology and physicochemical analysis for many years, leading the development of multiple innovative monoclonal antibody drugs and subunit vaccines. Through the transformation of achievements and cooperation with enterprises, he has promoted the approval of clinical trials or market launch by the US FDA and China NMPA.
  • CEO vuRoyal pharmaceutical company LLCHao Wang
    Hao Wang
    CEO vuRoyal pharmaceutical company LLC
    CEO,vuRoyal pharmaceutical company LLC(葳瑞医药), USA and China Dr. Hao Wang is currently the CEO of vuRoyal Pharmaceutical. He received his Ph.D. from MIT and MPA from Harvard University. Previously, Dr. Wang served as the vice president of the largest university-related research foundation, the Research Foundation for the State University of New York, and the chief information officer of the United States' largest comprehensive university system, the State University of New York. Hao was a partner/managing director of Accenture, a global 500 company, and served as vice president of Accenture China, leading Accenture's healthcare practice in Greater China. He had also served as deputy commissioner of the New York State Office of Mental Health. A graduate from Peking University, Dr. Wang served as an adjunct professor in several leading research universities such as Columbia University, Tsinghua University, University at Albany, and Xian Jiaotong University.
  • Director, Desert King InternationalDamian Hiley
    Damian Hiley
    Director, Desert King International
    Damian Hiley Product Manager for Vaccine Adjuvants, Desert King International, USA Since joining Desert King in 2012, Damian Hiley has played a crucial role in revolutionizing QS21 Vaccine adjuvants, leading to the pivotal launch of GMP QS21 in 2017. Beyond his substantial contributions to vaccine science, where his work underpins all commercially available vaccines with AS01 or Matrix M, Damian has spearheaded the company’s commitment to responsible forestry practices and the development of clonal plantations. His strategic oversight of the Pharmaceutical Exipient factory in Chile reflects his multifaceted expertise. Holding an MBA, Damian’s vision for sustainable innovation and leadership in global health advancements exemplifies his dedication to both environmental stewardship and medical progress.
  • Bioprocess Services Manager,Univercells TechnologiesRimenys Carvalho
    Rimenys Carvalho
    Bioprocess Services Manager,Univercells Technologies
    Rimenys Carvalho is a Biochemical Engineering and PhD in Bioengineering. After more than 10 years working in a academia, he joined Univercells Technologies in 2020 as Bioprocess Specialist, and currently, he is working as a Bioprocess Services Manager.
  • CSO, Dyadic InternationalRonen Tchelet
    Ronen Tchelet
    CSO, Dyadic International
    Ronen Tchelet, PhD: Ronen Tchelet joined Dyadic in May 2014 and has been Dyadic’s Vice President of Research and Business Development since January 2016 and later on became Dyadic’s CSO. Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral as an EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland. In the late 2000’s, he joined the API Division of TEVA Pharmaceutical Industries LTD., where he served as a Chief Technology Officer of Biotechnology. Dr. Tchelet leaded and directed the Research and Development Biotechnology department of TEVA’s fermentation plant in Hungary. In his work he managed and organized Biotechnology and Biosimilar projects that combined multidisciplinary areas such as development, operation, and production of API and biologics. In addition, from 2000 – 2005, Dr. Tchelet was the QA manager of COPAXONE® the flag ship TEVA¹s innovative drug. From 2007 through 2013, prior to joining Dyadic, Dr. Tchelet became the founder and the Managing Director of Codexis Laboratories Hungary kft. (CLH) and a Vice President of Codexis Inc. At CLH, he established a state-of-the-art laboratory for strain engineering and all aspects of fermentation work including process optimization and scaling up. It was during this time that Dr. Tchelet engaged with the C1 technology that was successfully developed for the Biofuel and the Bio-Industrial enzymes fields.
  • Staff Scientist, Vaccine Research Center, NIHBaoshan Zhang
    Baoshan Zhang
    Staff Scientist, Vaccine Research Center, NIH
    Dr. Baoshan Zhang is a Staff Scientist at Vaccine Research Center, NIH. He has broad experiences in vaccine development with a focus on structure-based immunogen design. Dr. Zhang leads optimizing and advancing methodologies that impact the development of novel molecules and proposes investment in alternate technologies. He is one inventor of the prefusion RSV F vaccine immunogens that are licensed to several major pharmaceutical companies. His ground-breaking work on RSV prefusion F molecules is the basis for mRNA1345 RSV vaccine developed at Moderna. Dr. Zhang currently focuses on vaccine development for infectious diseases as well as for non-communicable chronic diseases.
  • Professor of Vaccinology and Translational Medicine , University of OxfordSimon Draper
    Simon Draper
    Professor of Vaccinology and Translational Medicine , University of Oxford
    Simon Draper is Professor of Vaccinology and Translational Medicine at the University of Oxford. He was based at the Jenner Institute, Nuffield Department of Medicine from 2005 until Feb 2021 when he moved his laboratory to the Department of Biochemistry. The group's clinical team are based at the University's Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) on the Churchill Hospital site. The Draper Lab study vaccine-induced immunity, with a particular focus on antibody immunology and human malaria infection. A critical strength of the group is a strong dual focus on preclinical vaccine development in parallel with early-phase clinical vaccine testing and experimental medicine studies. In particular, the group's research interests span: strategies for improved vaccine antigen identification; development of improved vaccine delivery strategies; assessment of quantitative antibody correlates of protective immunity; and assessment of human vaccine-induced antibody responses to guide structure-based immunogen design and to better understand protective mechanisms of immunity.
  • MSAT lead, WuxiVaccineYao Pan
    Yao Pan
    MSAT lead, WuxiVaccine
    Dr. Yao Pan joined Wuxi Vaccine as MSAT lead and mainly responsible for process technology transfer and process validation. Before joining Wuxi Vaccine, she worked at WuXi Biologics Germany GmbH responsible for DP MSAT and project management departments. She has more than 8 years development and manufacturing experiences with vaccines, biologics as well as molecular diagnostics. Her expertise covers early development, new technology platform establishment, project management, process technology transfer and process validation. Before industrial career, she obtained her ph. D at Universität für Bodenkultur Wien and finished her post-doc at NIOO-KNAW.
  • Professor, Johannes Gutenberg-Universität, MainzHeinrich Hass
    Heinrich Hass
    Professor, Johannes Gutenberg-Universität, Mainz

    Heinrich Haas, Professor,  Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.

  • Professor/Academician,Institute of Process Engineering, CASGuanghui Ma
    Guanghui Ma
    Professor/Academician,Institute of Process Engineering, CAS
    Guanghui Ma is a professor of the State Key Laboratory of Biochemical Engineering (SKLBCE), Institute of Process Engineering (IPE). She is an academician of CAS in China and AIMBE fellow. She is serving as Director of the State Key Laboratory of Biochemical Engineering. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, respectively. She joined SKLBCE as a professor in 2001 and was promoted to the director in 2012. Her research interests focus on the preparation of uniform microspheres and microcapsules and their applications in biochemical engineering and biomedicine engineering, such as biochemical separation media, drug carriers, vaccine adjuvants (vaccine delivery systems), microcarriers for cell culture, and enzyme immobilization carriers. She has published over 500 papers, including Nature, Nat. Mater., Nat. Nanotechnol. Nat. Biomed. Eng., Nat. Commun., Sci. Adv., JACS, Adv. Mater., etc. She has more than 90 patents authorized, the technology and products have been commercialized in companies, and have been used in more than 500 affiliations in the world. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class prise of Science and Technology Award; 2020) of the Chemical Industry and Engineering Society of China, and Natural Science Award (1st Class; 2020) of the Chinese Society of Particuology.
  • Senior Scientist, Virogin BioTechKuan Zhang
    Kuan Zhang
    Senior Scientist, Virogin BioTech
    Dr. Kuan Zhang is the Senior Scientist at Virogin BioTech, specializing in anti-cancer immunotherapy and vaccine development. With a Ph.D. and postdoctoral research completed at VIDO-InterVac (Vaccine and Infectious Disease Organization) and OHRI (Ottawa Hospital Research Institute) respectively, she brings extensive expertise to her role in cancer immunotherapy research. Currently, Dr. Zhang leads the mRNA cancer therapeutic vaccines and oncolytic virus discovery pipelines in Virogin's R&D Department. She has received prestigious awards including the National High-Level University Graduate Program for Overseas Study, Mitax Accelerate Internship, Innovation Award from SK Province, and the Shanghai Key Industries Talent Special Award, among others.
  • Chief Strategy Officer, RIGHT FoundationHoon Sang Lee
    Hoon Sang Lee
    Chief Strategy Officer, RIGHT Foundation

    Dr. Hoon Sang Lee is a medical doctor and a global health expert, and currently the Chief Strategy Officer (CSO) of the RIGHT Foundation (Research Investment for Global Health Technology Foundation) and an adjunct professor at Yonsei University School of Public Health in Korea. Dr. Lee is also a member of Health Sector Advisory Committee of KOICA and a founding member of the Board for Korea Society of Global Health. Previously, he has worked as a health adviser for KOICA (Korea International Cooperation Agency) for bilateral health projects in various countries of Africa and Asia. Prior to KOICA, Dr. Lee worked as a medical officer at Korea CDC, managing national hepatitis B and measles immunization programme, and was involved in North Korea health programme for immunization support. Dr. Lee studied Economics and Public Policy at University of Chicago, received MD and PhD from Yonsei University School of Medicine and received MPH from Johns Hopkins School of Public Health.


  • Professor, Wuhan UniversityKe Xu
    Ke Xu
    Professor, Wuhan University

    Professor Xu focuses on the pathogenesis of respiratory RNA viruses (influenza, coronavirus) and the development of antiviral drugs and vaccines. More than 40 SCI papers have been published in internationally influential academic journals such as Science Translational Medicine, Cell Research, PNAS, Nature Communications, Protein & Cell, and PLoS Pathogens, cited more than 3300 times (including 5 ESI high-cited papers). The research results have been selected as a highlight or cover story by Science, Cell Research, Protein & Cell, Journal of Virology, and the China Science Foundation.

    The group made a series of progress in the mechanism of respiratory virus co-infection and broad-spectrum vaccine or drug candidates, promoted one antiviral drug into multinational clinical trials, and transformed a universal vaccine to deal with antigen drift. The above research results provide candidate strategies for epidemic prevention and control.


  • 活动日程
    2024-03-21
    2024-03-22
    2024-03-23
    2024-03-21
    08:45 -12:15
    Plenary Forum
    2024-03-21
    08:45-09:00
    Opening Remark
    2024-03-21
    09:00-09:45
    Plenary Panel:Next-generation vaccine technologies: innovations and challenges

    Ø   Explore the   latest advancements in vaccine technologies, such as mRNA vaccines and viral   vector platforms.

    Ø   Discuss the   potential impact of these innovations on global vaccine development and   deployment.

    Ø   Address   challenges related to safety, efficacy, and public perception of these   cutting-edge vaccine modalities.

       


    2024-03-21
    09:45-10:30
    Plenary Panel:Equitable access to vaccines: overcoming barriers and bridging Gaps
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Jiguo Zhang
    President, Vaccine Division, Fosun Pharma
    VIF World 2024-第5届疫苗创新国际论坛
    Hun Kim
    President of Global Business, SK Bioscience, South Korea
    VIF World 2024-第5届疫苗创新国际论坛
    Raman Rao
    CEO, Hilleman Laboratories
    2024-03-21
    11:00-11:30
    Keynote: The transformation of vaccinology: recent achievements and future prospects

    Advances in technology: reverse vaccinology 2.0, structural vaccinology, mRNA and more

     Remaining gaps: mucosal immunity, understanding the immunome, pandemic preparedness


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Michel De Wilde
    Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USA
    2024-03-21
    11:30-12:00
    Keynote: Advancing global health through vaccines
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Simon Draper
    Professor of Vaccinology and Translational Medicine , University of Oxford
    2024-03-21
    13:30 -18:00
    Stream A-Covid/Respiratory
    2024-03-21
    13:30-13:55
    Inhalable SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization

    Coronavirus disease pandemic has fostered major advances in vaccination technologies; however, there are urgent needs of mucosal immune responses and single-dose, non-invasive administration. We develop a SARS-CoV-2 vaccine for single-dose, dry-powder aerosol inhalation that induces potent systemic and mucosal immune responses. Our vaccine encapsulates proteinaceous cholera toxin B subunit-assembled nanoparticles displaying the SARS-CoV-2 RBD antigen (R-CNP) within microcapsules of optimal aerodynamic size, and such unique nano-micro coupled structure supports efficient alveoli delivery, sustained R-CNP release, and antigen presenting cell uptake, which are favourable for invocation of immune responses. Moreover, our vaccine successfully induces robust serological IgG and secretory IgA production, collectively conferring effective protection from SARS-CoV-2 challenge (including pseudovirus and the authentic virus) in mice, hamsters, and non-human primates. Finally, we also demonstrate a “mosaic iteration” of our vaccine that co-displays ancestral and Omicron’s antigens, thus extending the breadth of antibody response against co-circulating strains and transmission of Omicron variant. These findings support our inhalable vaccine as a promising candidate to prevent SARS-CoV-2 infection, disease, and transmission.

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Guanghui Ma
    Professor/Academician,Institute of Process Engineering, CAS
    2024-03-21
    13:55-14:20
    Self-amplifying RNA vaccines: growing evidence to support differentiation
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Igor Smolenov
    Chief Development Officer, Vaccines,Arcturus Therapeutics, USA
    2024-03-21
    14:25-14:50
    Africa’s new public health order: lessons from covid-19 pandemic
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Nicaise Ndembi
    Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
    2024-03-21
    14:50-15:15
    Reserved by Joinn Lab
    2024-03-21
    15:15-15:40
    TBC
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Nicholas Jackson
    三叶草生物研发总裁,英国
    2024-03-21
    15:40-16:00
    茶歇
    2024-03-21
    16:00-16:25
    A bivalent RSV mRNA vaccine developed based on Innorna's mRNA/LNP technology platform

    A diverse prophylactic vaccine pipeline has been bult up upon lnnorna's proprietary mRNA/LNP platform. US IND approvalhave been achieved for three vaccine candidates, including COVlD-19 mRNA vaccine, Herpes Zoster mRNA vaccine, andbivalent RSV mRAN vaccine. The bivalent RSV mRNA vaccine encoding stable pre-fusion conformation of F protein caninduce strong humoral immune response and Th1-skewed T cel response, and protected cotton rats and mice frominfection by either RSVA or RSV-8 without evidence of VAERD (vaccine associated enhanced respiratory disease).

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Zhangjing (Jim) Chen
    VP, Innorna, China
    2024-03-21
    16:25-16:50
    Reserved by ABMAX
    2024-03-21
    16:40-17:05
    Using non-changeable against changeable strategy to develop pan-HCoV vaccines
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Shibo Jiang
    Professor, Fudan University, China
    2024-03-21
    17:05-17:30
    RSV vaccine development (TBD)
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    王宾
    艾棣维欣首席科学家
    2024-03-21
    17:30-18:00
    Inhaled vaccine, new platforms for respiratory infectious diseases
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Tao Zhu
    CSO, Cansino Bio, China
    2024-03-21
    13:30 -18:00
    Stream B-Bioprocessing&Manufacturing
    2024-03-21
    13:30-13:55
    Innovations in vaccine technologies: manufacturing perspective
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Rajinder Suri
    CEO, DCVMN International, India
    2024-03-21
    13:55-14:25
    Intranasal immunization: device and formulation promises and challenges (TBD)
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Nektaria Karavas
    阿普塔医药业务发展总监
    VIF World 2024-第5届疫苗创新国际论坛
    Julie D. Suman
    阿普塔医药全球科学事务副总裁
    2024-03-21
    14:25-14:50
    The development of mRNA 2.0 vaccines in HealiRNA Biotechnology
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Zhong Chen
    Vice President, Suzhou HealiRNA Biotechnology
    2024-03-21
    14:50-15:15
    Innovations in end-to-end mRNA vaccine research, development and manufacturing: Progress and Partnerships of the mRNA Technology Development and Transfer programme

    ·         mRNA technology advances focusing on access and sustainability

    ·         overview and progress of the mRNA technology development and transfer programme

    ·         product pipeline for mRNA vaccines addressing neglected diseases

    ·         interpandemic sustainability of mRNA vaccine production expansions


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Petro Terblanche
    CEO, Afrigen Biologics, South Africa
    2024-03-21
    15:15-15:30
    Cell-based vaccine production: breaking new ground (TBD)
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Rimenys Carvalho
    Bioprocess Services Manager,Univercells Technologies
    2024-03-21
    15:30-16:00
    茶歇
    2024-03-21
    16:00-16:30
    TBC
    2024-03-21
    16:30-17:00
    Regulatory considerations for Microneedle Array Patches (MAPs), as a potential new delivery system for vaccines

    Microneedle Array Patches (MAPs) contain micron-sized projections that mechanically disrupt the outermost skin barrier (stratum corneum), in a minimally invasive manner, for delivery of APIs (vaccine or drug) to the underlying skin. As part of the Center of Excellence for Microneedle Array Patch (MAP) technology, PATH has partnered with Cardiff University to Chair a group that aims to provide independent scientific opinions and recommendations that help define the regulatory pathway for this emerging dosage form, and thus expedite clinical translation of the technology. This MAP Regulatory Working Group (MAP-RWG) includes representatives from both the commercial and academic sectors, vaccine development experts and representatives from national regulatory authorities, international pharmacopoeia and the WHO pre-qualification of medicines programme.

    MAP-RWG activities focus on key contemporary regulatory issues for MAPs that have been identified in consultation with stakeholders. Four parallel work streams have emerged and these aim to: (i) define the MAP dosage form; (ii) identify and categorise the MAP critical quality attributes (CQAs); (iii) develop standardised validated test methods to evaluate these CQAs and the quality of finished MAP products and/or the development of pre-clinical prototypes; and (iv) inform the microbiological requirements for MAP products (https://doi.org/10.1016/j.jconrel.2023.07.001). This talk will provide a general overview of progress against these workstreams and highlight the future directions for the MAP-RWG. More details about this endeavour can be found on the website: www.microneedleregulatory.org.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Maria Dul
    Research Associate, Cardiff University, UK
    2024-03-21
    17:30-18:00
    Innovating and digitalising mRNA vaccine and therapeutics production platform processes

    The RNA platform technology has emerged as one of the most promising and strategic technologies for rapid global vaccination, infectious disease control, biotherapeutics development, and preparedness for future healthcare challenges. Since this is a platform technology, the manufacturing infrastructure, the product and process analytical technologies, the product-process interactions, and learnings can be re-used or transferred from existing products to new products. To reach the full potential of this disease agnostic RNA platform, we are developing a set of synergistic technologies consisting of physical production processes (enzymatic RNA synthesis, downstream purification, and lipid nanoparticle formulation), analytical technologies, computer models and software. These technologies are co-developed under a patient-centric Quality by Digital Design (QbDD) framework. In this QbDD framework, first-principle or data-driven relationships are established between the critical process parameters (CPPs) of the production process and the critical quality attributes (CQAs) of the RNA vaccine and therapeutic product. The obtained models can be used for defining the design space and for advanced automation using model-predictive control. By combining the QbDD framework with the RNA platform, vaccines and therapeutics can be developed and mass-produced faster against a wide range of diseases. However, the regulatory approval of the digital tools used for process and product quality control is required in order to accelerate the development and manufacturing of RNA products. A form of production process template “pre-qualification” or “pre-approval” could expedite development and regulatory approval by re-using and computationally processing disease agnostic-prior knowledge, based on the platform nature of both the RNA vaccine manufacturing process and of the QbDD framework.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Zoltan Kis
    Lecturer, University of Sheffield, UK
    2024-03-21
    13:30 -18:00
    Stream C-Cancer Vaccine/RNA/Immunotherapy
    2024-03-21
    13:30-14:00
    Systems biology based rapid response to emerging infectious diseases -Developing immunotherapeutic interventions

    Mosquito-borne viruses, such as Dengue, Chikungunya, and Zika viruses, pose significant global health threats. Dengue, the most prevalent mosquito-transmitted viral disease, affects 50 to 100 million individuals annually, leading to over 25,000 deaths. Over the past decade, Chikungunya and Zika viruses have undergone substantial geographic expansion, causing multiple outbreaks worldwide. With climate change, increased global travel, and other factors expanding the range of disease-carrying mosquitoes, the risk of further outbreaks by these and other viruses remains high. Consequently, there is an urgent need to develop effective strategies for combating these pathogens, focusing on preventive and therapeutic interventions, including vaccines and passive immunotherapies. Addressing these risks is crucial to safeguard global health.

    Recent advancements in the field of systems biology have led to significant progress in the development of nucleic acid-based vaccines and monoclonal antibodies (mAbs) for the prevention and treatment of viral infections. This talk highlights the successful generation of these vaccines and mAbs, emphasizing their effectiveness in conferring protection against viral diseases. Specifically, the rapid protection offered by mAbs prophylaxis is discussed, along with compelling evidence demonstrating that the co-administration of nucleic acid-based mAbs and vaccines can provide both immediate and long-lasting immunity against infections. These findings have profound implications, particularly for populations with varying immune statuses, and hold great promise for resource-limited settings where traditional antibody therapies are economically unfeasible. This study underscores the potential of a systems biology approach in addressing global viral challenges and improving healthcare outcomes.

     

    This presentation highlights the utility of synthetic nucleic acid technology in the rapid development of immune therapeutics against infectious diseases.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Kar Muthumani
    , CSO, GeneOne Life Science, USA
    2024-03-21
    14:00-14:30
    Therapeutic DNA vaccine development (TBC)
    2024-03-21
    14:30-15:00
    mRNA vaccines against Clostridium difficile
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Mohamad-Gabriel Alameh
    Assistant Professor, University of Pennsylvania , USA
    2024-03-21
    15:00-15:30
    mRNA Vaccine : Pandemics and Beyond - for Vaccine Equity
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Kiat Ruxrungtham
    Director of Chula Vaccine Research Center, Chulalongkorn University
    2024-03-21
    15:30-16:00
    茶歇
    2024-03-21
    16:00-16:30
    TBC
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Ken Ishii
    Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
    2024-03-21
    16:30-17:00
    Novel mRNA technology and cancer vaccine development
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Hangwen Li
    CEO, Stemirna, China
    2024-03-21
    17:00-17:15
    Novel prime-boost strategy with mRNA and intratumoral oncolytic virus therapy for advanced cervical cancer

    Therapeutic cancer vaccines are promising next-generation treatments for cancers with tumor-associated or tumor-specific antigens. However, the cancer vaccine development encounters some major obstacles, such as the complication of intratumoral immune suppressive mechanism and the failure of generating sufficient self-antigen-specific cellular immune responses, et al. Virogin has developed a mRNA-and-oncolytic virus (OV)-based immune therapy that effectively induces tumor regression.

     

    In our mRNA therapeutic vaccine, an antigen presenting cells (APC)-targeting cancer antigen (HPV E6/7) was expressed and delivered through a mRNA-LNP platform. The vaccine elicited a robust peripheral CD8+ T-cell immune response and effectively prevented antigen-related cancer development in mouse. The antigen-specific T cells and other immune cells proficiently infiltrated into solid tumors leading to tumor regression. However, as the tumor progresses, intratumoral immune suppression intensifies, which is one of the major obstacles of cancer vaccines. This suppression restricted the infiltration of vaccine-induced immune cells and inactivated cytotoxic T cells in the tumor microenvironment (TME), limiting the therapeutic outcome, even when peripheral CD8+T cell immunity remained high. To address this challenge, we harnessed an OV therapy in combination with the mRNA vaccine as a prime-boost strategy. The OV intratumoral infection alters the TME through increasing cytotoxic T cells infiltration and polarizing neutrophils to antitumoral linages. As a results, the OV intratumoral boost following the intramuscular mRNA vaccination showed superior therapeutic efficiency in treating advanced solid tumors.

     

    Overall, Virogin's mRNA&OV prime-boost therapy offers a compelling solution for both preventing and treating cancers that are induced by HPV infection. The strategy proves highly effective in overcoming the intratumoral immune suppression. These dual approaches, each harnessing unique strengths, collectively underpin our comprehensive strategy in the battle against cancer with identified tumor antigens.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Kuan Zhang
    Senior Scientist, Virogin BioTech
    2024-03-21
    17:15-17:30
    SynNeogen® immunotherapy platform— New strategies for clinical development of therapeutic vaccines for chronic hepatitis B and prostate cancer
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Eric Yuenian Shi
    CEO, Chimigen, China
    2024-03-21
    17:30-17:45
    Clinical trial of an immunotherapy for the treatment of COVID-19
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Mingi Chang
    R&D Director, Advagene, China
    2024-03-22
    09:00 -12:30
    Stream F Novel Platform/Partnership
    2024-03-22
    09:00-09:25
    Structure-Based Immunogen Design for Effective mRNA Vaccines

    The potential of mRNA as a new class of medicines has been well demonstrated by the successfully development of mRNA vaccines for COVID-19 pedantic. Among many applications of mRNA for unmet medical needs, vaccine products currently dominate mRNA development pipelines. Using Respiratory Syncytial Virus mRNA vaccine development as a case study, the presentation illustrates how structure-based vaccine design could ensure precise vaccine targeting capabilities. The study provides insight into the importance of optimized protein molecules leading to enhanced stability, improved delivery, and ultimately, more potent immune responses.

    1. Atomic level structural information allows engineering of viral fusion proteins as potent vaccine immunogens

    2. Protein immunogens optimized for genetic delivery enables superior mRNA vaccine efficacy

    3. The strategy may be applied to type I viral fusion proteins and other protein immunogens facilitating the development of mRNA therapeutics


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Baoshan Zhang
    Staff Scientist, Vaccine Research Center, NIH
    2024-03-22
    09:25-09:50
    mRNA Nano-vaccines against EBV-positive Tumors

    More than ten kinds of tumors are associated with the infection of Epstein-Barr virus (EBV). For EBV-driven tumors, vaccines using EBNA1, LMP1, and LMP2 as antigens were found to induce anti-tumor immunity. Here,we developed novel mRNA nano-vaccines (EBV-mRNA/LNPs) against EBV-positive tumors. The EBV-mRNA/LNPs contained the innovative immune-enhancer (IE) introduced into the mRNA sequence encoding antigens and the ionizable lipid with new structure. Thus, the better safety and enhanced anti-tumor immunogenicity were observed in the investigator-initiated clinial trials (IIT) against nasopharyngeal carcinoma and NK/T lymphoma.

     


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    宋相容
    四川大学研究员, 威斯津联合创始人/总经理
    2024-03-22
    09:50-10:15
    nano-drug and delivery technology (TBD)
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Heinrich Hass
    Professor, Johannes Gutenberg-Universität, Mainz
    2024-03-22
    10:15-10:30
    Assessment of LNP Quality & Encapsulation Efficiency by Nano-Flow Cytometry
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Huijie Zhu
    Application Engineer,NanoFCM INC.
    2024-03-22
    10:30-10:45
    AstriVax, a novel vaccine platform committed to address real world vaccinology challenges

    Using innovative technology platforms, Hilleman Laboratories provides end-to-end product development solutionsirom concept to cGMP and Phase ll clinical development for affordable, high-value vaccines and biologics. lts latesticapability in GiP manufacturing of vaccines and biologics is able to pivot to manufacture vaccines for emergencyuse during pandemics. This is enabled through its modular, nimble and clever design which allows the facility toremain platfiorm-agnostic and product-independent. Leveraging various manufacturing platfomms for productinnovation, Hilleman Labs is committed to strengthening innovation in vaccine research and development for globahealth impact.

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Hanne Callewaer
    CEO, AstriVax, Belgium
    2024-03-22
    10:45-11:00
    茶歇
    2024-03-22
    11:00-11:25
    A novel mRNA vaccine for monkey pox

    The outbreak of monkeypox virus infection urgently needs effective vaccines. However, the vaccines approved so far are all based on live viruses, which raises safety concerns. mRNA vaccines have demonstrated their high efficacy and safety against SARS-CoV-2 infection. Here, we developed three mRNA vaccines encoding monkeypox proteins M1R and A35R, including A35R-M1R fusions with a signal peptide leading the A35R extracellular domain (VGPox 1 and VGPox 2) and a mixture of encapsulated full-length mRNAs for A35R and M1R (VGPox 3). All three vaccines induced anti-A35R total Immunoglobulin G (IgG) as early as day 7 following a single vaccination. However, only VGPox 1 and 2 produced anti-M1R IgG at early dates following vaccination, while VGPox 3 did not show significant anti-M1R antibodies until day 35. Similar results were also found for neutralizing antibodies and the T cell immune response. However, all mRNA vaccine groups post 2 dose vaccination completely protected mice from a lethal dose virus challenge and effectively cleared virus in lungs. Furthermore, VGPox 1 and 2 demonstrated superior anti-viral immunity compared to a sublethal VACV-WR virus at an earlier time point post vaccination. Collectively, our results indicate that the novel mRNA vaccines encoding the fusion protein of A35R and M1R—to allow extracellular presentation of both antigens—enhanced immunogenicity. A single dose of VGPox 1 and VGPox 2 can provide sterilizing protection against the lethal viral challenge even within 7 days post vaccination. They can therefore be an alternat

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    William Jia
    CSO, CNBG-Virogin, Canada
    2024-03-22
    11:25-11:40
    Assays for respiratory vaccines evaluation
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Emanuele Montomoli
    Co-founder& CSO, VisMederi, Italy
    2024-03-22
    11:40-12:05
    Research and development of a novel human DNA vaccine platform

    To combat COVID-19, all old vaccine platforms have been utilized, and some new vaccine platforms have been developed.  Here, we report the development of a novel DC-targeting DNA vaccine platform and its application to constructing human vaccines. Our preliminary clinical trial data indicate that these vaccines are safe and immunogenic,  and thus such DNA vaccines warrants further exploration and testing for a broader spectrum of diseases . 

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Xia Jin
    CEO/Co-founder, Cure Bio Tech, China
    2024-03-22
    12:05-12:30
    Developing a thermal stable mRNA RSV vaccine and beyond
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    刘元庆
    嘉晨西海生物 中国区CSO
    2024-03-22
    09:00 -12:30
    Stream E Vaccine Design/ Innovation
    2024-03-22
    09:00-09:30
    Harnessing germline immune memory for enhancing vaccine efficacy: new molecular mechanisms controlling memory establishment and persistence
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Diana Boraschi
    Distinguished Professor, Shenzhen Institute of Advanced Technology, China
    2024-03-22
    09:30-09:55
    Repeated exposure to SARS-CoV-2 antigens induces exceptionally broad and potent neutralizing immunity to major sarbecoviruses in humans including SARS-CoV-1

    Abstract/Bullet   Point

    Human antibody response to   SARS-CoV-2 has become increasingly complex as new variants continue to emerge   and spread across the world, resulting in multiple waves of breakthrough   infections with distinct antibody potency and breadth. During the outbreak of   Omicron subvariant BF.7 across the major cities in China in late 2022 after   extended lockdown, we have identified two individuals with exceptional plasma   neutralization to a diverse panel of sarbecoviruses including major   SARS-CoV-2 variants, SARS-CoV-1, and ACE-2-using bat and pangolin   coronaviruses. From the two individuals, we have isolated a total of 963   monoclonal antibodies (mAbs) and some of which demonstrated exceptionally   broad and potent neutralizing activity to SARS-CoV-1, all SARS-CoV-2 variants   tested including the most recent Omicron subvariant HK3, HV.1, JD.1.1 and   JN.1, as well as ACE-2-using bat and pangolin coronaviruses, resembling that   of corresponding plasma samples. Crystal and cryo-EM structural analysis   revealed some unique features of antibody epitope and recognition. While the   exact underlying mechanism for inducing such broad neutralizing antibodies   remains unknown, it is at least partially attributed to the repeated exposure   of SARS-CoV-2 antigens through both intramuscular and intranasal routes.  Discovery and in-depth analysis of these   broad and potent mAbs serves as the first and important step to inform the   development of next-generation antibody therapeutics and vaccine against   diverse human and animal coronaviruses.

       


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Linqi Zhang
    Professor, Tsinghua University
    2024-03-22
    09:55-10:20
    TBC
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    李少伟
    厦门大学教授
    2024-03-22
    10:20-10:45
    Novel vaccine development
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Aldo Tagliabue
    Chief Scientist, Shenzhen Institute of Advanced Technology, China
    2024-03-22
    10:45-11:00
    茶歇
    2024-03-22
    11:00-11:15
    Strengthening Innovation in Vaccine R&D for Global Health Access

    Using innovative technology platforms, Hilleman Laboratories provides end-to-end product development solutionsirom concept to cGMP and Phase ll clinical development for affordable, high-value vaccines and biologics. lts latesticapability in GiP manufacturing of vaccines and biologics is able to pivot to manufacture vaccines for emergencyuse during pandemics. This is enabled through its modular, nimble and clever design which allows the facility toremain platfiorm-agnostic and product-independent. Leveraging various manufacturing platfomms for productinnovation, Hilleman Labs is committed to strengthening innovation in vaccine research and development for globahealth impact.

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Raman Rao
    CEO, Hilleman Laboratories
    2024-03-22
    11:15-11:40
    Genetically engineered innovative bacterial vaccines
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Rong Xu
    CSO, Delonix Bioworks, China
    2024-03-22
    11:40-12:05
    TBC
    2024-03-22
    12:05-12:30
    B-cell responses in vaccinated people versus infected ones

    mRNA   vaccination for SARS-CoV-2 results in polyclonal antibody responses that   differ in antigen-specific breadth compared to viral infection, but it is   still unclear to what extent vaccine- and infection-induced B cell responses   differ at a B cell clonal level. We used a highly multiplexed panel of   DNA-tagged antigens including full SARS-CoV-2 Spike, S1, S2, receptor binding   domain (RBD), and nucleoprotein (N), as well as RBDs from up to 21 viral   variants to simultaneously label and sort over 5,000 antigen-binding B cells   from peripheral blood of 17 mRNA vaccinees, 28 infected patients and the   spleen and lymph nodes from the mediastinum and mesentery of 22 deceased   organ donors. Integrated analysis of single-cell tranome, BCR heavy and   light chain sequences identified an activated B cell phenotype found almost   exclusively in infected patients, and a highly enriched antigen-binding   memory B cell subset with evidence of recent germinal centre exposure. mRNA   vaccination stimulates a subset of BCR clonotypes preferentially, resulting   in greater antigen binding breadth. Secondary lymphoid tissues show   corresponding B cell phenotypes and similar antigenic variant breadth of   binding in donors who had been vaccinated versus infected prior to death.   Antigen-specific and convergent B cell and plasma cell clonal frequencies in   the bone marrow were greater in infected compared to vaccinated individuals,   particularly for RBD binders. These results systematically define human blood   and lymphoid tissue responses that differ following exposure to highly   similar spike antigens delivered by mRNA vaccination compared to infection.   Multiplexed DNA-tagged panel analysis of specific B cells will provide a   massive increase in throughput for human immunology studies in a variety of   disease and therapeutic contexts. 

     

       


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Fan Yang
    Professor, Shenzhen Institute of Advanced Technology, CAS
    2024-03-22
    09:00 -12:30
    Stream D-Novel Vaccine Development
    2024-03-22
    09:00-09:50
    Next generation pneumococcal vaccines
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    George Siber
    Adjunct Professor of Medicine, Johns Hopkins Medical School Visiting Researcher, Institute of Microbiology, Chinese Academy of Sciences President, Siber Biotechnologies LLC
    2024-03-22
    09:50-10:20
    TBC
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Yao Pan
    MSAT lead, WuxiVaccine
    2024-03-22
    10:20-10:40
    TBC
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Chongyang Liang
    Prof., Jilin University;Senior Advisor, Scientific Advisor, ProMab Forethought; Scientific Advisor, Changchun BCTH
    2024-03-22
    10:40-11:00
    茶歇
    2024-03-22
    11:00-11:15
    The thermophilic filamentous fungus, C1 - an extraordinary platform for the production of prophylactics for humans and animals
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Ronen Tchelet
    CSO, Dyadic International
    2024-03-22
    11:15-11:40
    Pharmaceutical Research of immunoprophylaxis for antimicrobial resistant superbug
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Quanming Zou
    Professor, Army Medical University, China
    2024-03-22
    11:40-12:00
    Helicobacter pylori vaccine development
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Fan Fan
    Vice president of Chengdu Olymvax Biopharmaceuticals Inc., Head of Olymvax R&D institution
    2024-03-22
    12:00-12:20
    Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    祝先潮
    瑞宙生物CEO
    2024-03-22
    13:30 -18:00
    Stream I Clinical Trial, Market Access
    2024-03-22
    13:30-14:00
    Regulatory strategy to accelerate vaccine approval (TBC)
    2024-03-22
    14:00-14:20
    TBC
    2024-03-22
    14:20-14:40
    Reserved by 美莱德
    2024-03-22
    14:40-15:10
    Evaluation on mucosal respiratory COVID -19 vaccines in clinical trials

    1.     Safety and immunogenicity of an orally inhaled adv5 vectored COVID -19 vaccine

    2.     Immunogenicity of the orally inhaled adv5 vectored COVID -19 vaccine using as a booster in primed population

    3.     Efficacy of the orally inhaled adv5 vectored COVID -19 vaccine using as a booster

    4.     Environmental impact assessment for the use of the orally inhaled adv5 vectored COVID -19 vaccine in clinics


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Jingxin Li
    Deputy Department Head, Jiangsu CDC, China
    2024-03-22
    15:10-15:40
    Randomized double blind Clinical Trial on Covid-19 vaccine

    SARS-CoV-2 belongs to the coronavirus family and is a pathogen that can spread across races and easily cause respiratory diseases. The symptoms of the disease caused by the virus are mainly fever, cough and dyspnea, and imaging changes accompanied by patchy diffuse infiltration of the lungs. The symptoms of the disease caused by the virus are mainly fever, cough and dyspnea, and imaging changes accompanied by patchy diffuse infiltration of the lungs. Genome sequencing analysis indicated that the virus is different from any known virus. WHO named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disease caused by the virus was named COVID - 19. WHO listed the epidemic as a public health emergency of international concern. Prof. Dr. M. Raza Shah lead Phase 1 trial of Sinopham vaccine in Pakistan and also remained country PI of phase-3 clinical trial of mRNA based vaccine. He will be talking about both trial in the conference and will be sharing his experiencing and some results.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Raza Shah
    Professor and Director University of Karachi, Bangladash
    2024-03-22
    15:40-16:00
    茶歇
    2024-03-22
    16:00-16:30
    TBC
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Andrew Wong
    BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, China
    2024-03-22
    16:30-16:45
    Driving R&D towards global public health and health equity for Vaccine: RIGHT foundation’s approach

    The RIGHT Foundation is a research funding agency dedicated to supporting global health research and development (R&D), established with of goal of providing a platform to catalyse collaborations between Korean and international researchers and partners to develop essential health technologies as global public goods. The presenstation will discuss about how RIGHT Foundation provides overview of how RIGHT Foundation support the R&D on vaccine to improve global health equity in the area of vaccine

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Hoon Sang Lee
    Chief Strategy Officer, RIGHT Foundation
    2024-03-22
    13:30 -18:00
    Stream H Adjuvant/Mucosal/Delivery
    2024-03-22
    13:30-14:00
    QS-21 for Advanced Adjuvants and its impact on modern vaccines
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Hao Wang
    CEO vuRoyal pharmaceutical company LLC
    VIF World 2024-第5届疫苗创新国际论坛
    Damian Hiley
    Director, Desert King International
    2024-03-22
    14:00-14:25
    Evolution of flagellin adjuvant towards clinical application
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Joon Haeng Rhee
    Professor, Chonnam National University Medical School, South Korea
    2024-03-22
    14:25-14:50
    Interferons and inflammasomes in adjuvant induced immune responses

    The presentation will address the mode of action of polymeric vaccine adjuvants, focusing on how the physicochemical properties of the particle/polymer regulate innate and adaptive immune responses.  There will be a focus on recent work showing roles for canonical and noncanonical inflammasomes and nucleic acid sensors in adjuvanticity.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Ed Lavelle
    Professor, Trinity College Dublin, Ireland
    2024-03-22
    14:50-15:15
    Mucosal adjuvants
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Elizabeth Norton
    Associate Professor,Tulane University, USA
    2024-03-22
    15:15-15:40
    Advances in adjuvants, protein expression, and delivery technologies continue to give protein vaccines the edge; Advax-CpG adjuvant

    The development of safe and effective vaccines is a key requirement to conquering pandemic and other infectious disease threats as well as potentially offering treatments for chronic diseases such as cancer and Alzheimer’s disease. After a surge of innovation approximately 50 years ago with introduction of the first recombinant protein and polysaccharide conjugates vaccines and adjuvants based on squalene oil emulsions and saponins, the field became relatively quiet in respect of innovations. All that changed with the COVID-19 pandemic which arguably has seen the greatest number of new vaccine technology innovations introduced all in just a few years, including approval of mRNA, DNA and adenoviral vector delivery approaches, new combination adjuvants, and use of structural modelling approaches using artificial intelligence and nanotechnology-based analytical techniques to design more stable vaccine antigens. The COVID-19 pandemic has emphasized the importance of ongoing innovation in the vaccine field.  This current wave of innovation is spilling over into other vaccine programs, including new and improved vaccines against HIV, tuberculosis and malaria, plus treatments for allergy, cancer and Alzheimer’s disease. This talk will highlight these transformative innovations, particularly relating to Vaxine’s Advax-CpG adjuvant and how this is transforming the future for protein-based vaccines.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Nikolai Petrovsky
    Founder, Vaxine, Australia
    2024-03-22
    15:40-15:55
    茶歇
    2024-03-22
    15:55-16:20
    Intranasal vaccination can build effective mucosal immunity wall against Omicron infection

    We generated a replication-incompetent recombinant adenovirus type 5, Ad5-S-Omicron and evaluated in an IIT to test intranasal vaccination in people who had inactivated vaccines. The vaccine is safe and well-tolerated without any SAEs. All participants who completed 2 doses remained no infection between Dec.2022 to April 2023. Nasal mucosal lining fluids collected after intranasal booster contained secretary IgA (sIgA) that can bind to at least 10 spike proteins of Omicron subvariants and pre-Omicron strains. Instillation of nasal lavage fluids into mouse nostril conferred protection against Omicron challenge. We found that nasal sIgA is over 100-fold more potent than serum IgG in neutralizing Omicron subvariant XBB. Intranasal booster using Ad5-S-Omicron can establish an effective immunity wall against infection of Omicron subvariants. We also developed a rapid and convenient assay to detect nasal sIgA for predicting the risk of infection.

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    陈凌
    广州实验室研究员
    2024-03-22
    16:20-16:45
    TLR5 pathway-based mucosal adjuvant for design of subunit mucosal vaccines

    Respiratory mucosa is the first barrier to prevent the invasion of various respiratory viruses. On the other hand, respiratory mucosa becomes a main portal for the invasion and infection of respiratory viruses. Fortifying the frontier of respiratory tract with enhanced mucosal immune defense is critical for prevention against respiratory virus invasion, infection and transmission. Intranasal (i.n.) immunization can induce local mucosal IgA antibody and T cell responses besides comprehensive systemic immune response. Flagellin, as a TLR5 agonist, is an established mucosal adjuvant for enhancing mucosal IgA responses by i.n. immunization. Nasal epithelial cells (NECs) are the first sentinel cells to be exposed to antigen and play an important role in the mucosal adjuvant activity of flagellin. We found that the flagellin-activated NECs functionally modulate airway DCs and convey the regulation for enhancement of IgA production. Based on the TLR5 activity of flagellin, we constructed a series of recombinant flagellin for development of mucosal adjuvants. A subunit mucosal vaccine targeting the phosphoprotein (P) of RSV was developed by integrating the target immunogen into flagellin frame for inducing mucosal immune responses against virus infection by i.n. immunization. We also designed a multi-valent chimeric triple-RBD immunogen 3R-NC, which can elicits broad-spectrum immune responses and potent mucosal immune responses, especially the mucosal IgA antibody responses in the upper-respiratory tract by i.n. immunization. The immune responses confer protection against viral infection in the upper and lower respiratory tracts, indicting potential for prevention against infection and transmission of SARS-CoV-2.

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    鄢慧民
    复旦大学附属公卫中心研究员
    2024-03-22
    16:45-17:00
    Engineered design of mucus penetration nanoparticles for inhalable vaccines

    Mucosal drug delivery has gained significant attention due to its advantages over traditional injection, e.g., convenience and avoidance of blood-borne diseases. During mucosal administration, a key factor that must be considered is the mucus barrier. Various surface modification strategies, including PEG and zwitterionic polymer, have been explored for mucus-penetrating carriers. However, the microenvironment of mucus varies under different physiological or pathological conditions, and the influence of surface properties of nanoparticles on their mucus penetration in various microenvironments remains unclear. In our study, we have prepared a comprehensive library of amine-, carboxyl-, and PEG-modified nanoparticles with controlled surface ligand densities. We demonstrated that surface properties are critical factors in determining their mucus penetration, which is affected by the mucus pH microenvironments, the type of surface modification, and the ligand density of NPs. PEG- and amine-modified particles exhibited pH-independent immobilization under iso-density conditions, while carboxyl-modified particles exhibited enhanced movement only in weakly alkaline mucus. Biophysical analysis indicated that the penetration behavior was mediated by the NP-mucin interaction, including electrostatic interaction and hydrogen bond. Based on these mechanistic insights, we have engineered mucosal vaccine delivery nanoparticles. In a respiratory syncytial virus (RSV) vaccine model, these particles have been shown to enhance both humoral and cellular immune responses, leading to the production of antigen-specific IgA in mucosal compartments and IgG in the serum. Our study reveals the underlying mechanisms of mucus penetration and provides valuable insights for the rational design of prophylactic and therapeutic mucosal vaccines.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Bingbing Sun
    Professor, Dalian University of Technology, China
    2024-03-22
    17:00-17:15
    Innovative and High-Performing Lipids for mRNA Delivery

    mRNA vaccines are a new class of vaccines that have been used in the COVID-19 pandemic. In the post-COVID-19 era, mRNA will show great potential in various preventive and therapeutic vaccines. The efficient delivery technology of mRNA is the core technology and lipid nanoparticle obtained great success in COVID-19. However, the present technology is far from ideal. It suffers from low protein expression and non-specific expression in the liver, leading to the safety risk of vaccination. In this talk, I will present a powerful strategy to modulate ionizable lipids for LNP application by multi-component reaction. A large IL toolbox was established simply and efficiently, allowing us to identify the top-performing ILs in delivering mRNA. We established a novel delivery platform for mRNA application with high expression and organ selectivity as well as high safety. 

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    陈永明
    中山大学教授
    2024-03-22
    17:15-17:30
    Synthetic lipopeptides as vaccine adjuvants
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Haibo Li
    Professor, Army Medical University, China
    2024-03-22
    17:30-18:00
    Adjuvant& delivery technology
    2024-03-22
    13:30 -18:00
    Stream G Novel Vaccine Development
    2024-03-22
    13:30-14:00
    A phase 1, placebo-controlled safety and immunogenicity trial evaluating a vaccine consisting of polyvalent, multi-subtype, DNA plasmids with matching adjuvanted gp120 proteins

    Despite progress in HIV diagnosis rates, linkage to care and treatment, and the increasing availability of chemoprophylaxis, an estimated 1·5 million new HIV infections occurred in 2021 worldwide. Therefore, the development of a safe and effective HIV vaccine remains an important objective toward ending the HIV epidemic. I will provide an update on the global effort of HIV vaccine development and more specifically the results of HVTN 124, a phase 1, placebo-controlled safety and immunogenicity trial evaluating a vaccine consisting of polyvalent, multi-subtype, DNA plasmids with matching adjuvanted gp120 proteins (polyvalent DNA-protein HIV vaccine, PDPHV). In addition to the excellent safety profile, PDPHV demonstrated excellent immunogenicity outcomes including a combination of both magnitude and breadth. These immune responses compared very favorably to those observed in contemporaneous early-phase vaccine candidate studies and were of magnitudes that exceeded those associated with vaccine protection in efficacy trials. Further evaluation of this combination in larger trials with more robust statistical methods is warranted.

    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Shan Lu
    Emeritus Professor, University of Massachusetts Medical School, USA
    2024-03-22
    14:00-14:25
    An update of vaccine development on Heptatis E
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    James Wai Kuo Shih
    Senior Advisor, Xiamen Innovax Biotech, China
    2024-03-22
    14:25-14:50
    lnvestigation of virus-like structure vaccine based on technological strategy of lipid delivery
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Qihan Li
    Professor,IMBCAM, China
    2024-03-22
    14:50-15:15
    Combination vaccine development
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Kutub Mahmood
    Scientific Director at PATH, USA
    2024-03-22
    15:15-15:35
    Development of in vitro - assembled multivalent VLP vaccine for norovirus infection

    Introduction

    Human noroviruses are the primary viral pathogens causing acute gastroenteriis worldwidc, lcading to a considerable economic burdenWhile the development of a norovirus vaccine has been regarded as significant, any vaccine has not been licensed yet. An effecive norovirusvaccine development has been dificul due to the wide genetic and antigenic diversity of noroviruses and the co-circulalion of multiple variants ofvarious genotypes. In the context of this diversity, effective vaccine must elicit broad protective immunity

    Results

    We confirmed high-eficient soluble expression of the recombinant VP1 proteins in E. col and the improvements in purity andhomogeneity of the norovirus VP1-based VPs assembled in viro. The trivalent norovirus VP vaccine candidates showed excellent immuneresponses with 2-dose administralions in the animal studies and the vaccine candidate-induced antibodies showed the ability to block the bindingof norovirus VLPs and HBGA. Furthermore, GLP-based toxicology and pharmacology data sets confrmed that VLP vaccine candidates did notinduce any unexpected toxicity or pharmacological outcomes associated with CNS, respiratory or cardiology aspects

    Conclusion

    The results demonstrate that E. col-derived norovirus VLPs enable mass and rapid production of norovirus vaccines. Moreover, in vitroassembly of purified VP1 proteins faclitated production of high quality VLP vaccine candidates with high homogeneity and low impurities, whichmight result in increased efficacy and reduced side effects. The results in preclinical studies suggest that the E. col-derived trivalent VlP has apotential as a norovirus vaccine candidate with high efficacy and safety. Thus, this study supports that the E.col-derived & self-assemblednorovirus VLPs are worthy to proceed into clinical study for further development as a vaccine candidate.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Deog-Young Choi
    CEO, InThera, South Korea
    2024-03-22
    15:35-16:00
    茶歇
    2024-03-22
    16:00-16:20
    Progress toward AIDS vaccines

    Without an effective vaccine, AIDS remains an infectious disease that has a huge impact on global public health. An important feature of HIV is the high level of genetic diversity which results in up to 30% difference in the amino acid sequences of the envelope glycoprotein among HIV-1 subtypes. Importantly, the viral evolution within infected individuals is faster than the development of potent neutralizing antibodies in the same infected individuals. These observations pose a huge challenge to the development of effective AIDS vaccines. Since the viruses among different HIV-1-infected individuals are highly divergent, a vaccine that cannot elicit broadly reactive immune responses will not be able to control infections by diverse HIV-1 variants. Therefore, developing an AIDS vaccine that can induce broadly neutralizing antibodies (bnAbs) is a key objective that needs to be achieved urgently. Our previous results showed the requirement of several years for bnAbs to mature, the key role of genetic variation of HIV-1 in bnAb production, and the importance to efficiently trigger proper unmutated common ancestors of bnAbs. Our recent studies indicate that the neutralizing strength and breadth of vaccine-induced antibody responses can be improved by the modification of envelope glycoprotein trimers to increase their stability, the sequential immunization mimicking natural infection, and the nanoparticle vaccine technology. Therefore, an in-depth understanding of the evolutionary pathways of HIV-1 and further optimization of immunization regimens can accelerate the development of effective AIDS vaccines.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Feng Gao
    Professor & Director, Jinan University
    2024-03-22
    16:20-16:40
    Development of Nanoparticle Human Vaccines Utilizing A Proprietary IC-BEVS Platform
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Enqi Du
    GM/CSO, Nano Microgene, China
    2024-03-22
    16:40-17:00
    Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice
    2024-03-23
    09:00 -12:00
    Stream J Veterinary Vaccine
    2024-03-23
    09:00-09:30
    Developing a ‘One Health’ Nipah virus vaccine to protect animal and public health

     To support efforts to develop vaccines to combat emerging viral zoonoses, we are developing a Nipah virus (NiV) vaccine for use in pigs, which would reduce the risk that NiV poses to the Asian pig industry, livestock keepers and public health. Pig-to-human transmission was responsible for the first and most severe NiV outbreak. This outbreak caused severe and lasting economic costs to the Malaysian pig industry. Despite the threat NiV poses to some of the most pig dense regions of the world, no vaccines are currently available. We have therefore evaluated the immunogenicity of recombinant NiV glycoprotein (G or F) based vaccine candidates delivered as protein subunits or by viral or mRNA vectors in pigs. Three vaccine candidates have been evaluated for efficacy and shown to confer a high degree of protection following a prime-boost regimen. In addition to providing a platform for the development of a NiV vaccine for pigs, we hope these studies will also benefit ongoing human vaccine development efforts. Two scenarios are envisaged for how a NiV vaccine for pigs could be deployed: (1) as part of a government vaccine bank and used in an outbreak situation; consequently, a vaccine that provides a rapid onset of immunity after a single immunisation would be preferable, and (2) incorporated into routine vaccination programmes to reduce the risk of NiV outbreaks occurring; a dual purpose/bivalent vaccine would make this a more financially viable approach. We are evaluating an approach to address the requirements for both scenarios i.e., a single dose NiV vaccine that could also be used as a bivalent vaccine. We hypothesised that a single immunisation with live attenuated pseudorabies virus (PrV) expressing both NiV G and F will induce protective responses. Live attenuated PrV strains are highly efficacious vaccines that can be recombined to encode heterologous antigens from other pathogens, thus making live attenuated PrV an ideal candidate for a multivalent vaccine vector. Since PrV vaccination is widely practiced across the NiV-endemic region, there is the potential that a PrV vaccine expressing NiV glycoproteins could be routinely used to establish NiV immunity in Asian pigs.  We engineered the attenuated PrV Bartha strain to express NiV G and F. Immunisation of pigs with this recombinant PrV induced neutralising antibody titres following the booster immunisation comparable to previously tested vaccine candidates. PrV-specific responses were comparable to those elicited by wild type PrV Bartha immunisation. Further studies are now required to determine the efficacy against both NiV and PrV.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Simon Graham
    Professor, The Pirbright Institute, UK
    2024-03-23
    09:30-10:00
    The Importance of specific antibodies in the Development of VLP based vaccines

    In this lecture,taking foot-and-mouth disease as an example,  speaker will propose the thinking of quality control of virus-like particle vaccine by introducing the necessity and significance of the research and development of foot-and-mouth disease virus-like particles. With the advantages of nanobodies, the specific nanobodies for virus-like particles were screened, and the site recognition characteristics were used to establish an immunological method for the quantification of virus-like particles, which achieved the objective, accurate and rapid goal of the quality control of FMD new vaccines. At the same time, the neutralization characteristics of specific nanobodies were used to further track the neutralization mechanism and specific neutralization sites, providing a theoretical and preliminary basis for the use of nanobodies as a new prevention and control product.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Huichen Guo
    Professor, Lanzhou Veterinary Research Institute, China
    2024-03-23
    10:00-10:30
    Targeting Chimeric Subunit Vaccines against Porcine Respiratory Pathogens

    Three chimeric subunit vaccines was developed using reverse vaccinology (RV) technique by Reber. The recombinant proteins chosen for the three vaccines contains multi-epitopes from the porcine reproductive and respiratory syndrome virus (PRRSV), Mycoplasma hyorhinis and Mycoplasma hyopneumoniae. PRRSV-negative piglets vaccinated with PRRSQ subunit vaccines demonstrated significantly lower (P < 0.05) mean rectal temperatures, respiratory scores, lung lesions and PRRSV nucleic acid level within interstitial pneumonia, as well as reduced type 1, type 2 PRRSV and HP-PRRSV viremia compared to unvaccinated pigs after challenge. Vaccination with PRRSQ also induced PRRSV-specific INF-g cellular immunity and complement neutralizing antibody in pigs. Vaccination with chimeric subunit vaccines of Mycoplasma hyorhinis and Mycoplasma hyopneumoniae also significantly reduce porcine arthritis polyserositis, and  pneumonia. The data presented supports the claims that the commercialized novel sub-unit vaccines are effective tools in the control of heterologous PRRS viruses and mycoplasma. This chimeric fusion platform has also proven to be effective in controlling and eliminating respiratory pathogens of immunosupressive diseases in advanced mammals such as porcine and human.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Frank Chang
    CSO, Reber Genetics, China
    2024-03-23
    10:30-11:00
    茶歇
    2024-03-23
    11:00-11:30
    mRNA based vaccine development for animal diseases
    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Caiyi Fei
    Co-founder& VP, Therarna
    2024-03-23
    11:30-12:00
    Next-Generation High-Yield Baculovirus/Insect Cell Protein Expression System—qBac® Bacmid

    The qBac® baculovirus/insect cell protein expression system has been engineered with gene knockouts that impact protein yield, incorporates siRNA to inhibit host cell apoptosis, and features fine-tuned expression levels of tranion factors. This has resulted in a suite of robust and distinctive protein expression solutions centered around the baculovirus expression vector, significantly enhancing the expression of exogenous proteins to 1-5 g/L.

    In the vaccine industry (particularly subunit vaccines), we leverage the systemic advantages of the qBac® Bacmid to support a comprehensive five-in-one technology platform, which includes gene-engineered subunit vaccines, peptide/epitope vaccines, gene-deleted vaccines, nucleic acid vaccines, and live vector vaccines. This platform underpins our strategic deployment in animal vaccine product lines, including livestock, poultry, aquaculture, and pet vaccines.


    嘉宾
    VIF World 2024-第5届疫苗创新国际论坛
    Xiaodong Xu
    Prof., Northwest A&F University
    Opening Remark
    Plenary Panel:Next-generation vaccine technologies: innovations and challenges
    Plenary Panel:Equitable access to vaccines: overcoming barriers and bridging Gaps
    VIF World 2024-第5届疫苗创新国际论坛
    Jiguo Zhang
    President, Vaccine Division, Fosun Pharma
    张继国先生担任复星医药疫苗事业部总裁,此前曾在多家跨国公司中国以及全球总部担任高管,也曾担任上市公司睿智医药CEO,在疫苗领域、并购整合、公司管理等方面积累了丰富经验。张继国先生以优异的成绩毕业于北京大学医学部以及北京大学国家发展研究院,毕业后曾留校任教。张继国先生也是虹博基因的联合创始人兼CEO,同时也是中国疫苗行业协会委员,中国大健康业务发展协会(CHBD)荣誉会长。
    VIF World 2024-第5届疫苗创新国际论坛
    Hun Kim
    President of Global Business, SK Bioscience, South Korea
    VIF World 2024-第5届疫苗创新国际论坛
    Raman Rao
    CEO, Hilleman Laboratories

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


    Keynote: The transformation of vaccinology: recent achievements and future prospects
    VIF World 2024-第5届疫苗创新国际论坛
    Michel De Wilde
    Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USA

    Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community and is member of several Scientific Advisory Boards

    From  2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at sanofi pasteur where he drove the development and licensure  of a number of products.

     

    From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine.

     


    Keynote: Advancing global health through vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Simon Draper
    Professor of Vaccinology and Translational Medicine , University of Oxford
    Simon Draper is Professor of Vaccinology and Translational Medicine at the University of Oxford. He was based at the Jenner Institute, Nuffield Department of Medicine from 2005 until Feb 2021 when he moved his laboratory to the Department of Biochemistry. The group's clinical team are based at the University's Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) on the Churchill Hospital site. The Draper Lab study vaccine-induced immunity, with a particular focus on antibody immunology and human malaria infection. A critical strength of the group is a strong dual focus on preclinical vaccine development in parallel with early-phase clinical vaccine testing and experimental medicine studies. In particular, the group's research interests span: strategies for improved vaccine antigen identification; development of improved vaccine delivery strategies; assessment of quantitative antibody correlates of protective immunity; and assessment of human vaccine-induced antibody responses to guide structure-based immunogen design and to better understand protective mechanisms of immunity.
    Inhalable SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization
    VIF World 2024-第5届疫苗创新国际论坛
    Guanghui Ma
    Professor/Academician,Institute of Process Engineering, CAS
    Guanghui Ma is a professor of the State Key Laboratory of Biochemical Engineering (SKLBCE), Institute of Process Engineering (IPE). She is an academician of CAS in China and AIMBE fellow. She is serving as Director of the State Key Laboratory of Biochemical Engineering. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, respectively. She joined SKLBCE as a professor in 2001 and was promoted to the director in 2012. Her research interests focus on the preparation of uniform microspheres and microcapsules and their applications in biochemical engineering and biomedicine engineering, such as biochemical separation media, drug carriers, vaccine adjuvants (vaccine delivery systems), microcarriers for cell culture, and enzyme immobilization carriers. She has published over 500 papers, including Nature, Nat. Mater., Nat. Nanotechnol. Nat. Biomed. Eng., Nat. Commun., Sci. Adv., JACS, Adv. Mater., etc. She has more than 90 patents authorized, the technology and products have been commercialized in companies, and have been used in more than 500 affiliations in the world. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class prise of Science and Technology Award; 2020) of the Chemical Industry and Engineering Society of China, and Natural Science Award (1st Class; 2020) of the Chinese Society of Particuology.
    Self-amplifying RNA vaccines: growing evidence to support differentiation
    VIF World 2024-第5届疫苗创新国际论坛
    Igor Smolenov
    Chief Development Officer, Vaccines,Arcturus Therapeutics, USA

    Igor Smolenov is the Chief Development Officer of Arcturus Therapeutics. Dr. Smolenov is an infectious disease physician dedicated to the clinical development of novel vaccines, with a proven record of accomplishment in both small biotechnology and large pharmaceutical companies. He contributed to the successful development and licensure of several innovative vaccines.

    Before joining Arcturus, Dr. Smolenov was the Executive Vice President at Clover Pharmaceuticals, where he built a robust team able to rapidly generate pivotal clinical data leading to adjuvanted COVID-19 vaccine authorization. Prior to that, Dr Smolenov served as Therapeutic Area Head, leading the development of several seasonal influenza vaccines in Seqirus (CSL), and Head of Clinical Development in Moderna Therapeutics, leading the initiation of the first clinical trials of mRNA vaccines in humans. At Novartis Vaccines, Dr. Smolenov contributed to the development and global licensure of meningococcal vaccines (Menveo, Bexsero, and MenABCWY) and the overall commercial success of the meningococcal vaccines franchise.

    Igor Smolenov graduated from Volgograd State Medical University, Russia, and holds MD, Ph.D., and Doctor of Science (Habilitation) degrees from this university. Before starting his career in the industry, he passed multiple academic steps from junior researcher to professor and head of the Allergy/immunology department of the university. He is the author of more than 50 publications in peer-reviewed journals in clinical pharmacology and vaccine development.


    Africa’s new public health order: lessons from covid-19 pandemic
    VIF World 2024-第5届疫苗创新国际论坛
    Nicaise Ndembi
    Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
    Dr. Nicaise Ndembi is Senior strategic Advisor on Sciece and Policy to the Africa Centres for Disease Control and Prevention Director General and currently Associate Professor, Division of Epidemiology and Prevention at the Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, USA. Dr. Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Public Health, Japan and a Research Professor within the same Institution. He is a Principal Investigator on numerous grants including US National Health Institute (NIH). He has authored/co-authored more than 180 publications in peer-reviewed journals. He is the Editor-in-Chief of the Journal of Public Health in Africa (JPHIA), AIDS Research and Therapy (ARTY), and serves on various WHO and US NIH Advisory Groups.
    Reserved by Joinn Lab
    TBC
    VIF World 2024-第5届疫苗创新国际论坛
    Nicholas Jackson
    三叶草生物研发总裁,英国
    茶歇
    A bivalent RSV mRNA vaccine developed based on Innorna's mRNA/LNP technology platform
    VIF World 2024-第5届疫苗创新国际论坛
    Zhangjing (Jim) Chen
    VP, Innorna, China
    Zhangjing Chen, VP, Clinical Science in Vaccine and Infectious disease, Innorna • Lead the development strategy and study execution for Innorna’s proprietary mRNA prophylactic vaccines since joining in 2022. • Sixteen-year journey in industry, concentrating in clinical development of anti-infective agents and prophylactic vaccines in Pfizer, Astrazeneca, Janssen and native biotech companies. • Lead or contribute to the development strategy, protocol generation, study execution, IND/CTA/BLA application, and post-marketing strategy in China for various vaccine products, including pneumococcal conjugated vaccine, COVID-19 vaccine, Respiratory Syncytial Virus vaccine, extra-intestinal pathogenic Escherichia coli vaccine. • Nine-year clinical practice in Infectious Disease in Huashan Hospital Fudan University and participated into international multi-center clinical trials or national registration clinical trials for several novel antimicrobials. • Master of Internal Medicine, Shanghai Medical College, Fudan University • Bachelor of Clinical Medicine, Shanghai Medical College, Fudan University
    Reserved by ABMAX
    Using non-changeable against changeable strategy to develop pan-HCoV vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Shibo Jiang
    Professor, Fudan University, China
    Dr. Shibo Jiang is a Professor at the Shanghai Institute of Infectious Disease and Biosecurity of Fudan University, Shanghai, China. His main research interest is the development of antiviral drugs and vaccines. He has published 572 papers (total IF: 7,662, average IF: 13.4) in SCI journals such as Cell (x3), Nature (x2), Science (x2), Lancet (x4), CNS’ sister journals (x71), with total 45,327 citations and an h-index of 105. He has applied for 104 patents, 54 of which were issued, and 11 of them were licensed out with 3 classes of innovative drugs and medical products used in clinics.
    RSV vaccine development (TBD)
    VIF World 2024-第5届疫苗创新国际论坛
    王宾
    艾棣维欣首席科学家
    王宾 教授,, 艾棣维欣生物执行董事、董事会主席及首席科学家,复旦大学基础医学院特聘教授,中国疫苗行业协会核酸疫苗分会主任委员。王宾博士在疫苗研发领域拥有超过30年的经验。王宾博士在美国Wistar研究所和宾夕法尼亚大学医学院工作期间,和导师David Weiner教授最早发明了DNA疫苗技术。回国之后,王宾博士在创新疫苗领域,尤其是DNA疫苗以及创新佐剂方面有着深入的研究,累积发表150余篇SCI论文,获得超过40项国际发明专利,主持并参与了国家“863”重大项目、自然科学基金重点项目、 “十二五”重大新药创制、“十三五”国家传染病防治重大专项、“十四五”重点专项等重要科研课题。设计和参与了多项治疗性疫苗和预防性疫苗的临床试验。王宾博士也是Emerging Microbes & Infections及Human Vaccines & Immunotherapeutics等国际期刊的编委会成员。
    Inhaled vaccine, new platforms for respiratory infectious diseases
    VIF World 2024-第5届疫苗创新国际论坛
    Tao Zhu
    CSO, Cansino Bio, China

    Dr. Tao Zhu, Ph.D. the University of Pittsburgh

    Co-founder and Chief Scientific Officer of CanSino Biologics Inc. 


    Dr. Zhu is a member of the 14th National Committee of the Chinese People's Political Consultative Conference (CPPCC) and the “Healthy China Construction” professional committee of the Chinese Peasants and Workers Democratic Party. 


    Dr. Zhu focuses on the research and development of biological products. He established multiple core technology platforms, including viral vector, polysaccharide protein conjugate vaccine, VLP recombinant vaccine and mRNA vaccine technology at CanSino. Multiple projects led by him have been selected as national “Major Science and Technology Projects for New Drug Creation” and “Major Science and Technology Projects for Infectious Diseases”. 


    Dr. Zhu has led the team to develop a series of vaccine products, of which 6 vaccine products have been registered and marketed, another 7 vaccine products are in different stages of clinical studies. He co-developed the adenovirus vector-based Ebola virus vaccine (2018), the Recombinant COVID-19 Vaccine (Convidecia, 2021), the Recombinant COVID-19 Vaccine for Inhalation(Convidecia Air, 2022), and the Recombinant COVID-19 XBB Vaccine for Inhalation(2023), with the team of Academician Chen Wei of the Institute of Bioengineering, Academy of Military Medical Sciences, all of which have been marketed. Especially, Convidecia Air is the first developed inhalation vaccine product in the global. Menhycia, which was approved in 2021, is currently the only quadrivalent meningococcal conjugate vaccine on the market in China. Dr. Zhu also holds over 50 patents and 70 publications, including 15 papers from The Lancet publishers.


    Innovations in vaccine technologies: manufacturing perspective
    VIF World 2024-第5届疫苗创新国际论坛
    Rajinder Suri
    CEO, DCVMN International, India
    Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN. Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.
    Intranasal immunization: device and formulation promises and challenges (TBD)
    VIF World 2024-第5届疫苗创新国际论坛
    Nektaria Karavas
    阿普塔医药业务发展总监
    Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America focusing on nasal drug delivery. She has contributed to multiple nasal development programs, supported commercial scale up and product launches for New Drug Applications (NDA) using an Aptar delivery device for key pharmaceutical clients across different therapeutic indications. Nektaria holds a Bachelor of Science from McGill University, Montreal, Canada
    VIF World 2024-第5届疫苗创新国际论坛
    Julie D. Suman
    阿普塔医药全球科学事务副总裁
    Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce. She is a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001. In 2008, Dr. Suman received an award from the Greater Baltimore Committee for Entrepreneurial Spirit.
    The development of mRNA 2.0 vaccines in HealiRNA Biotechnology
    VIF World 2024-第5届疫苗创新国际论坛
    Zhong Chen
    Vice President, Suzhou HealiRNA Biotechnology
    Doctor of Pharmacy, Postdoctoral Fellow at UNC Chapel Hill, USA. During his academic career, he was awarded the title of Associated Professor. Presided over and/or participated in a number of National Natural Science Foundation projects and national Science and Technology major projects for new drug development, and participated in the successful marketing of small molecule innovative drugs. He has published 20 academic papers in international journals and authorized 10 Chinese invention patents. In the past 5 years, he has focused on the development and industrialization of nucleic acid drug delivery vectors (mRNA, siRNA) and nucleic acid medicinal chemistry, and has applied for a number of PCT patents. He has accumulated a lot of industrialization experience in nucleic acid drug project selection, delivery vector development and CMC research.
    Innovations in end-to-end mRNA vaccine research, development and manufacturing: Progress and Partnerships of the mRNA Technology Development and Transfer programme
    VIF World 2024-第5届疫苗创新国际论坛
    Petro Terblanche
    CEO, Afrigen Biologics, South Africa
    Professor Petro Terblanche has a successful track record in the strategic and operational management of technology intensive organizations. She has played a key part in the design and implementation of South Africa’s biotechnology strategy. She holds the position of Chief Executive Officer of Afrigen Biologics (Pty)Ltd based in Cape Town, South Africa. Afrigen hosts the WHO Global mRNA technology development and transfer Hub and has a mRNA Covid 19 vaccine candidate in development as part of a global program to build capacity and capabilities in LMICs to design, develop and produce mRNA vaccines. Prof Terblanche is the author of more than 200 scientific publications and conference papers in public health. Petro holds several Board positions and serves on a number of scientific advisory boards in the public health sector. She was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.
    Cell-based vaccine production: breaking new ground (TBD)
    VIF World 2024-第5届疫苗创新国际论坛
    Rimenys Carvalho
    Bioprocess Services Manager,Univercells Technologies
    Rimenys Carvalho is a Biochemical Engineering and PhD in Bioengineering. After more than 10 years working in a academia, he joined Univercells Technologies in 2020 as Bioprocess Specialist, and currently, he is working as a Bioprocess Services Manager.
    茶歇
    TBC
    Regulatory considerations for Microneedle Array Patches (MAPs), as a potential new delivery system for vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Maria Dul
    Research Associate, Cardiff University, UK
    Maria, a chemist by training (MSc from Jagiellonian University in Krakow, Poland), completed her PhD in the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, working on ‘Engineering an oral delivery system for insulin’. She then moved to Cardiff University and in the last decade her research has predominantly focused on the development of innovative microneedle-based technologies for the delivery of small molecules, peptides, proteins and nucleic acids into the skin. Maria has extensive experience in the microneedle field, having used a range of microneedle prototypes in both pre-clinical and clinical projects. She is currently lead researcher in an international collaboration between key stakeholders (Microneedle Array Patch (MAP) Regulatory Working Group), which aims to advance the regulatory science of microneedle-based dosage forms by informing future guidance and developing standardized test methods for proposed MAP products.
    Innovating and digitalising mRNA vaccine and therapeutics production platform processes
    VIF World 2024-第5届疫苗创新国际论坛
    Zoltan Kis
    Lecturer, University of Sheffield, UK
    Dr. Zoltán Kis is a Lecturer at the Department of Chemical and Biological Engineering at The University of Sheffield, and an Honorary Lecturer at the Department of Chemical Engineering, Imperial College London. Zoltán is leading a multidisciplinary team that is innovating and digitalising RNA vaccine and therapeutics production platform technologies. His work is addressing the challenges of producing large volumes of RNA-based vaccines and therapeutics, rapidly, at high quality and at low cost in a disease-agnostic manner. Zoltán has previously worked as a Research Associate in the Future Vaccine Manufacturing Hub at Imperial College London. He obtained his Ph.D. in Bioengineering from Imperial College London, UK, holds an M.Sc. in Applied Biotechnology and a B.Eng. in Chemical with Biochemical Engineering.
    Systems biology based rapid response to emerging infectious diseases -Developing immunotherapeutic interventions
    VIF World 2024-第5届疫苗创新国际论坛
    Kar Muthumani
    , CSO, GeneOne Life Science, USA
    Dr. Muthumani has been working on basic immunology and translational science, especially in vaccine and immunotherapy areas. He completed his MS and Ph.D. at the Madurai Kamaraj University and post-doctoral fellowship at the Perlman School of Medicine at the University of Pennsylvania, PA, USA, focused on viral pathogenesis, nucleic acid vaccines, and immune therapies. He has directed a translational research laboratory focusing on synthetic nucleic acid technology to develop novel vaccines and immunotherapies for emerging and reemerging infectious diseases at The Wistar Institute, PA-USA, as part of preclinical studies using small animals and non-human primates and facilitated the translation of several vaccine candidates into the human clinical trials. In addition, he was associated with, as an investigator or co-investigator, several grants, including the prestigious NIH-HVDDT program grant for HIV-1 vaccine development, a highly selective NIH directors translational grant for universal influenza vaccine development, Sponsored Research Agreement grant for studying the virus and host receptor interactions (Dengue, MAYV, POWV, and CHIKV), Defense Advanced Research Projects Agency (DARPA), WW Smith grant, and Emerson Collective Cancer Research grant regarding immunotherapeutics. Over the years, his laboratory developed, evaluated, and demonstrated the efficacy of vaccine immunogens for Human immunodeficiency virus (HIV), Chikungunya Virus (CHIKV), and Middle East Respiratory Syndrome (MERS), ZIKA, Nipah, POWV, MAYV, and SARS-CoV2 virus. Notable was that the synthetic nucleic acid vaccines MERS- Coronavirus (NCT03721718), Zika virus (NCT02887482), and SARS-CoV-2 (NCT04336410) were the first vaccines into human clinical testing. As a significant contributor to the vaccine literature, he has published 128 highly cited peer-reviewed scientific articles and book chapters, with a Google H-index of 39. In addition, the research articles appeared in scholarly journals, awarded 22 patents, and filed 25 patents (total of 47) for the work. Given his stellar scientific background and accomplishments, Dr. Muthumani is uniquely positioned to lead and tackle new challenges for emerging and reemerging diseases of public health importance or relevance.
    Therapeutic DNA vaccine development (TBC)
    mRNA vaccines against Clostridium difficile
    VIF World 2024-第5届疫苗创新国际论坛
    Mohamad-Gabriel Alameh
    Assistant Professor, University of Pennsylvania , USA

    Dr. Alameh is an Assistant Professor at Department of Pathology and Laboratory Medicine in the University of Pennsylvania and the Children Hospital of Philadelphia (CHOP), and the co-director of the Engineered mRNA and Targeted Nanomedicine Core at the Penn RNA Institute for RNA Innovation.

     

    Dr. Alameh obtained his Ph.D. in Biomedical Engineering in 2017 from Polytechnique Montreal under the supervision of Dr. Michael D. Buschmann and joined the laboratory of the now Nobel laureate Dr. Drew Weissman to develop multiple nucleoside-modified messenger RNA (mRNA) vaccines, study the adjuvant effect of different ionizable lipids, and develop new lipid-based delivery systems. Dr. Alameh explored the development of a novel lipid nanoparticle (LNPs) based adjuvant platform and developed potent mRNA-based vaccines against various pathogens including Clostridium difficile.

     

    His research program lies at the interface of nanotechnology, material science, engineering, and medicine to develop prophylactic and therapeutic nucleic acid-based delivery platforms and optimize their manufacturing. His team studies, and model Structure-Activity Relationships of material for improved delivery systems (e.g., lipid nanoparticle therapeutics), and nucleic acid-based vaccines. Their efforts are focused on dissecting the effect of different structural and physicochemical features of the delivery systems and their components (e.g., ionizable lipids, and helper lipids in lipid nanoparticles) on the performance, stability, and toxicity of these systems before and after interaction with the biological environment to develop vaccines against enteric pathogens, in utero and postnatal gene editing, and regenerative medicine.

     

    Current research projects include synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acid-based therapeutics (e.g., messenger RNA encoded base editors); development of mRNA-based vaccines against enteric pathogens, and the development of high-throughput screening platforms to assess material biocompatibility and toxicity.


    mRNA Vaccine : Pandemics and Beyond - for Vaccine Equity
    VIF World 2024-第5届疫苗创新国际论坛
    Kiat Ruxrungtham
    Director of Chula Vaccine Research Center, Chulalongkorn University
    Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)
    茶歇
    TBC
    VIF World 2024-第5届疫苗创新国际论坛
    Ken Ishii
    Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
    Novel mRNA technology and cancer vaccine development
    VIF World 2024-第5届疫苗创新国际论坛
    Hangwen Li
    CEO, Stemirna, China
    Dr. Hangwen Li holds a Ph.D from MD. Anderson Cancer Center. He was Assistant Professor at the Department of Pharmacology and Clinical Therapy of MD Anderson Cancer Center and successively received grants and awards from the US Department of Defense. He is currently a distinguished researcher of Dongfang Hospital of Tongji University, a member of the Vaccine International Cooperation Promotion Branch of the China Association For Vaccines, and a permanent member of the Nucleic Acid Vaccine Branch of the China Association For Vaccines. Dr. Li has more than 19 years of experience in the field of RNA and cancer immunotherapy. His research fields include tumor immunotherapy, RNA drugs and cancer stem cells. He has published more than 30 SCI articles and publications, and his articles have been cited for more than 3000 times. In 2021, he won the National Science and Technology System's award for Distinguished Individual in Fighting the Covid-19 Pandemic, and in 2022, he won the “Gold Gathering Award” in the Shanghai Global Talents Innovation & Entrepreneurship Competition. In 2016, Dr. Li returned to China and founded StemiRNA, which is the first company in Asia that focuses on the research and development of innovative mRNA drugs and vaccines. StemiRNA has now developed into a global leader and the first domestic platform innovative drug enterprise for mRNA vaccine and drug research and development in China. Its self-developed lipid polymer nano carrier (LPP) technology platform has been granted patents in Europe, America and other places. StemiRNA’s pipelines include mRNA vaccines and drugs for a series of infectious diseases (including COVID-19, influenza, etc.), tumors, and rare diseases.
    Novel prime-boost strategy with mRNA and intratumoral oncolytic virus therapy for advanced cervical cancer
    VIF World 2024-第5届疫苗创新国际论坛
    Kuan Zhang
    Senior Scientist, Virogin BioTech
    Dr. Kuan Zhang is the Senior Scientist at Virogin BioTech, specializing in anti-cancer immunotherapy and vaccine development. With a Ph.D. and postdoctoral research completed at VIDO-InterVac (Vaccine and Infectious Disease Organization) and OHRI (Ottawa Hospital Research Institute) respectively, she brings extensive expertise to her role in cancer immunotherapy research. Currently, Dr. Zhang leads the mRNA cancer therapeutic vaccines and oncolytic virus discovery pipelines in Virogin's R&D Department. She has received prestigious awards including the National High-Level University Graduate Program for Overseas Study, Mitax Accelerate Internship, Innovation Award from SK Province, and the Shanghai Key Industries Talent Special Award, among others.
    SynNeogen® immunotherapy platform— New strategies for clinical development of therapeutic vaccines for chronic hepatitis B and prostate cancer
    VIF World 2024-第5届疫苗创新国际论坛
    Eric Yuenian Shi
    CEO, Chimigen, China
    Over 35 years of experience in biomedical research and development specializing in cancer research and translational medicine. Prior to founding Chimigen Bio, Dr Shi was Co-founder/CEO of OncoVent, a clinical-stage biopharmaceutical company. OncoVent’s leading candidate, Oregovomab, is a First-in-Class cancer immunotherapeutic drug belonging to the therapeutic cancer vaccine, currently in the global phase III stage. He was Vice President of the Academy of Clinical Research and Translational Medicine in Jiangsu Province since 2011. He led 4 research projects sponsored by the China National Science Foundation and 1 cancer early diagnosis research sponsored by the National Key Technology R&D Program for the 12th Five-year Plan of China. Prior to that Dr Shi was a full Professor at Albert Einstein College of Medicine, New York, where he led 12 national research programs funded by the U.S. National Cancer Institute (NCI), U.S. Department of Defense (DOD), and American Cancer Society. Dr Shi received his doctorate degree in biochemistry in 1989 at Dartmouth Medical School. Upon graduation from Peking University School of Medicine in 1983, Dr Shi was admitted into CUSBEA (China-U.S. Biochemistry Examination Application), a very selective and competitive program leading to graduate study at Dartmouth.
    Clinical trial of an immunotherapy for the treatment of COVID-19
    VIF World 2024-第5届疫苗创新国际论坛
    Mingi Chang
    R&D Director, Advagene, China
    • Director of Research and Development, Advagene Biopharmaceuticals Inc • Director of Biologics Division, RuenHuei Biopharmaceuticals Inc. • Research Fellow, Protein Drug Project, Development Center for Biotechnology (DCB). • Assistant Professor. Section of Immunology, Department of Medicine, Tzu Chi University
    Structure-Based Immunogen Design for Effective mRNA Vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Baoshan Zhang
    Staff Scientist, Vaccine Research Center, NIH
    Dr. Baoshan Zhang is a Staff Scientist at Vaccine Research Center, NIH. He has broad experiences in vaccine development with a focus on structure-based immunogen design. Dr. Zhang leads optimizing and advancing methodologies that impact the development of novel molecules and proposes investment in alternate technologies. He is one inventor of the prefusion RSV F vaccine immunogens that are licensed to several major pharmaceutical companies. His ground-breaking work on RSV prefusion F molecules is the basis for mRNA1345 RSV vaccine developed at Moderna. Dr. Zhang currently focuses on vaccine development for infectious diseases as well as for non-communicable chronic diseases.
    mRNA Nano-vaccines against EBV-positive Tumors
    VIF World 2024-第5届疫苗创新国际论坛
    宋相容
    四川大学研究员, 威斯津联合创始人/总经理

    宋相容,药剂学博士,生物学博士后,哈佛医学院纳米医学和免疫学访问教授,现为四川大学华西医院生物治疗全国重点实验室的研究员/博士生导师,入选国家级青年人才,国家重点研发计划首席科学家,威斯津生物联合创始人/总经理。

    从事基于靶向递送的创新药物研发近20年,聚焦mRNA创新药物研究10余年,突破了mRNA药物研发的关键底层技术,布局了mRNA序列、递送载体和智能制造设备等核心专利。

    主持国家重点研发计划、国家科技重大专项、国家自然科学基金等课题30余项,在Nat Comm、Sci Adv等发表一作/通讯SCI论文60余篇。

    申请发明专利73项(国际专利10项),已授权23项、实现企业转让4项;牵头转予药企的成果3项。

    主持的纳米佐剂(WGa01)已获紧急使用许可(EUA)上市、3个1类mRNA新药已经进入了临床试验。

    相关研究荣获:国家科技部2022年度全国颠覆性技术创新大赛优胜奖(最高奖,排名第1),任Sig Transduct Target Ther、Asian J Pharm Sci、Eur J Pharm Sci编委 、中国医药生物技术协会纳米生物技术分会委员、中国疫苗行业协会核酸疫苗分会委员、美中药协SAPA西部创新中心理事长等。


    nano-drug and delivery technology (TBD)
    VIF World 2024-第5届疫苗创新国际论坛
    Heinrich Hass
    Professor, Johannes Gutenberg-Universität, Mainz

    Heinrich Haas, Professor,  Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.

    Assessment of LNP Quality & Encapsulation Efficiency by Nano-Flow Cytometry
    VIF World 2024-第5届疫苗创新国际论坛
    Huijie Zhu
    Application Engineer,NanoFCM INC.
    After graduating from the University of New South Wales,she has been responsible for the application development and pre-sales technical support of nano-flow cytometry, with solid theoretical foundation and rich experience in LNP characterization.
    AstriVax, a novel vaccine platform committed to address real world vaccinology challenges
    VIF World 2024-第5届疫苗创新国际论坛
    Hanne Callewaer
    CEO, AstriVax, Belgium

    July 2022 - current : AstriVax

    CEO and Co-founder


    July 2021 – July 2022: KU Leuven

    Entrepreneur in Residence


    June 2018 – August 2022: Oxurion

    Head Regulatory Affairs

    Business Development

    Chief Operating Officer


    March 2009 – May 2018: GSK Vaccines

    Regulatory Affairs

    Vaccine Development Leader


    Sept 2008 – Feb 2009 – Gevers Patents

    Trainee patent attorney


    About

    Diverse experience in the life science industry exhibiting a unique capability to merge operational execution and strategic development - implementation. Global industry experience in large pharmaceutical industry as well as into smaller biotech environment. Strong experience in development of commercial, late or early stage vaccines, monoclonal antibodies, peptides and small molecules. Regulatory affairs, drug and vaccine development expertise blended with business and corporate development. Proven track record to build up and lead diverse teams. Innovative mindset, with demonstrated ability to think beyond commonly accepted boundaries, understanding well different personalities and able to perform complex and challenging tasks and capable to distil the essence from the noise.


    茶歇
    A novel mRNA vaccine for monkey pox
    VIF World 2024-第5届疫苗创新国际论坛
    William Jia
    CSO, CNBG-Virogin, Canada

    Biography :

    n  Senior Scientist, Brain Research Centre, University of British Columbia (UBC), Canada (09.1994-07.2019)

    n  Associate Professor of Neurosurgery, UBC (tenured) (09.1994-07.2019)

    n  Chief Scientific Officer, Co-founder of Virogin Biotech Ltd (05.2015- present)

    n  Chief Scientific Officer, CNBG-Virogin Biotech Ltd (2019- present)

     

    Dr. Jia obtained his PhD in neurobiology from University of British Columbia (1991), MSc. Psychology (1987) from Dalhousie University in Canada, and BSc. Biology from Fudan University (1982) in China. In 2015, Dr.Jia co-founded Virogin Biotech, an oncolytic virotherapy company in Canada. He is currently the chief scientific officer of Virogin and CNBG-Virogin to develop oncolytic viruses and novel vaccines.


    Assays for respiratory vaccines evaluation
    VIF World 2024-第5届疫苗创新国际论坛
    Emanuele Montomoli
    Co-founder& CSO, VisMederi, Italy
    Emanuele Montomoli was graduated in Life Sciences at University of Siena in 1997. Since November 2016 he was appointed by the Department of Molecular Medicine of University of Siena as full Professor on Public Health. Since April 2018 to 2021 he was nominated in the Executive Board of the Toscana Life Sciences Foundation. Since 2010 he he was elected as President of the Board for the “Master in vaccinology and drug development” at University of Siena. Since 2019 he was nominated in the Executive Board of Eurocine vaccines AB. In 2008 he funded VisMederi srl, an enterprise involved in laboratory activities for vaccines and antiviral drugs clinical trials. Actually, he has a role of Chief Scientific Officer in VisMederi srl. Since 1994 he has carried out epidemiological research, surveillance networks for infectious diseases and serological assays for clinical trials for vaccines. In 2015 he was appointed as scientific coordinator for a project funded by EU-IMI (Innovative Medicine Initiative) titled “Standardization and development of assays for assessment of influenza vaccine correlates of protection”. He is the author of more than 200 papers, as well as numerous abstracts and letters, published in international scientific journals.
    Research and development of a novel human DNA vaccine platform
    VIF World 2024-第5届疫苗创新国际论坛
    Xia Jin
    CEO/Co-founder, Cure Bio Tech, China

    Xia JIN,MD, PhD is currently an executive director and Chief Executive Officer of Immuno Cure BioTech Ltd., Hong Kong. He has hold a number of academic positions previously, including Professor of Fudan University Shanghai Public Health Clinical Center, and its Director of Vaccine & Immunology Center; Distinguished Professor of the Chinese Academy of Science(CAS), and Deputy Director of Vaccine Research Center of the Institute Pasteur of Shanghai, and Deputy Director of CAS Molecular Virology & Immunology Key Lab. Before returning China, he has been a tenure-track Associate Professor of University of Rochester. His research focuses on the immune pathogenesis of human infectious diseases such as HIV and Dengue, and pre-clinical and clinical development of vaccines against these and other human pathogens.  He has published in 140 papers in peer-reviewed journals such as Science,J. Exp. Med.,J. Clin. Inv.,Nat. Commn., J Virol., Vaccine etc..

    Developing a thermal stable mRNA RSV vaccine and beyond
    VIF World 2024-第5届疫苗创新国际论坛
    刘元庆
    嘉晨西海生物 中国区CSO
    刘元庆,1988年毕业于上海复旦大学医学院,曾任上海中山医院普外科医生。博士就读于比利时布鲁塞尔自由大学, 师从Patrick De Baetselier教授探索肿瘤微环境和肿瘤疫苗。2008年加入赛诺菲巴斯德从事肿瘤疫苗研发,2010-2021年在赛诺菲巴斯德法国研发总部,先后主导多个核心课题,涉及传染病疫苗、小儿疫苗、新佐剂等,并作为工业界专家参加欧盟创新医学共同体,对于创新疫苗慨念验证、临床申报、工业化发展具有丰富的经验。2021年加入嘉晨西海任CSO,旨在助力加快中国mRNA疫苗和药物的研发。
    Harnessing germline immune memory for enhancing vaccine efficacy: new molecular mechanisms controlling memory establishment and persistence
    VIF World 2024-第5届疫苗创新国际论坛
    Diana Boraschi
    Distinguished Professor, Shenzhen Institute of Advanced Technology, China
    Diana Boraschi is an immunologist that built her experience in academic institutions and industrial settings in her home country (Italy) and abroad (USA, France, Austria, Korea, Brazil). She is Senior Associate Researcher at the Italian National Research Council (where she served as Institute Director) and at the Stazione Zoologica Anton Dohrn in Napoli, Italy, and Academician of the Accademia dei Fisiocritici. She is currently serving as Distinguished Professor at the Department of Pharmacology at the Shenzhen Institute of Advanced Technologies (SIAT) of the Chinese Academy of Sciences, in Shenzhen, China. She is author of over 200 peer-reviewed research articles in immunology (h-index 67, over 16000 citations), in addition to many books and book chapters, and inventor in eight patents. In 2017, she has received an honorary PhD degree by the University of Salzburg (Austria), in 2020 the High-Level Talents Program Award for Foreign Scholars, and in 2022 the Chinese Government Friendship Award. She is listed within the first 2% scientists worldwide since 2017 and in the first 1% since 2020. Her area of expertise is innate immunity and inflammation, in particular in relation to autoimmune, inflammatory and degenerative diseases, and vaccine development. Her focus on macrophages and cytokines of the IL-1 superfamily (a bioactive IL-1 domain is known as the “Boraschi loop”), and the interaction of engineered nanomaterials with immunity in humans and environmental species. She is particularly involved in higher education training activities in Europe, Asia, Africa, and South America, with a focus on poverty-related diseases.
    Repeated exposure to SARS-CoV-2 antigens induces exceptionally broad and potent neutralizing immunity to major sarbecoviruses in humans including SARS-CoV-1
    VIF World 2024-第5届疫苗创新国际论坛
    Linqi Zhang
    Professor, Tsinghua University
    Professor Linqi Zhang is the Director of the Comprehensive AIDS Research Center at Tsinghua University. Prof. Zhang's research focuses on HIV-1 pathogenesis and vaccine development, and has recently expanded to the field of emerging and re-emerging human viral pathogens such as SARS-CoV-1/2 and MERS-CoV. Using cutting-edge antibody and combinatorial antigen library techniques, Prof. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Professor Zhang is the recipient of the National Outstanding Young Scientist Award, privileged Changjiang Professorship, and Bayer and Vanke Chair professor. He has published extensively and is among the most cited Chinese researchers in the field of microbiology and immunology. Professor Zhang has also served as a member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases,and was recently elected as a Foreign Fellow of the African Academy of Sciences.
    TBC
    VIF World 2024-第5届疫苗创新国际论坛
    李少伟
    厦门大学教授
    李少伟博士,厦门大学生命科学学院/公共卫生学院教授,国家传染病诊断试剂与疫苗工程技术研究中心疫苗组组长,福建省翔安创新实验室副主任。入选国家百千万人才工程、教育部新世纪优秀人才和《自然•生物技术》评选的2016年度全球转化研究TOP20(大陆学者首次入选),担任世界卫生组织疫苗产品开发咨询委员会(WHO-PDVAC)成员(20名成员中唯一中国学者)。作为核心研究人员研制全球首个戊肝疫苗、首个国产HPV疫苗和国内首个第三代艾滋诊断试剂等新药。主持国家863计划项目、新药创制国家科技重大专项、重点研发计划和国家自然科学基金等;获国家科技进步二等奖、国家技术发明二等奖、中国专利金奖、求是杰出科技成就集体奖和中国科协求是杰出青年成果转化奖等;在《细胞•宿主与微生物》《自然•微生物学》《自然•通讯》等发表SCI论文120余篇;获得发明专利授权29项。
    Novel vaccine development
    VIF World 2024-第5届疫苗创新国际论坛
    Aldo Tagliabue
    Chief Scientist, Shenzhen Institute of Advanced Technology, China
    Aldo Tagliabue has been active for more than 4 decades in research, development, management, strategic planning and establishing facilities for innovative vaccines. After a long career as experimental immunologist and as manager of large cooperation R&D projects in public-private partnerships funded by the European Commission, Aldo Tagliabue has been involved in the creation of start-up companies in the field of human vaccines, such as AchilleS Vaccines Srl, a company of the Siena Vaccine Hub (Italy), and BCGene in São Paulo (Brazil). He has recently founded Veterna Srl, to develop mRNA vaccines for veterinary infections. His scientific background is based on early experience in the public sector, including a postdoctoral period at the NCI/NIH in Bethesda, MD, USA, from 1976 to 1979, and an internship at the McMaster University in Hamilton, Ontario, Canada in 1981. This was the basis for his subsequent experiences in industry. In 1982, he joined the Sclavo Research Center in Siena (Italy) as Head of Immunology, and in 1990 he became R&D Director at the pharmaceutical company Dompé in L’Aquila (Italy). In the early 2000s, he was Deputy Director at the International Vaccine Institute in Seoul (Republic of Korea), a WHO and UN initiative, and also served as a member of the Programme/Policy Committee of the GAVI Alliance Board. In 2011, with Rino Rappuoli he created the Sclavo Vaccine Foundation, whose mission is to sustain and promote vaccines for poverty related diseases. From 2014 to 2017, he was Director General of the Regional Foundation for Biomedical Research in Milan, the funding agency of the Lombardy Region (Italy) for health sciences. He was Adjunct Professor of Immunology at the University of Bologna (Italy) from 1996 to 2006, and Adjunct Professor at the Seoul National University from 2003 to 2005. He is author of more than 120 publications in immunology and vaccinology and inventor in 10 patents. Since 2017 is Senior Associated Scientist of the Italian National Research Council. In September 2021 he moved to China, at the Shenzhen Institute for Advanced Technology, as Visiting Professor supported by Chinese Academy of Science with a President International Fellowship. Recently he was awarded with a professorship in the Yangtze River Scholar Fellowship Program for his experience in vaccinology.
    茶歇
    Strengthening Innovation in Vaccine R&D for Global Health Access
    VIF World 2024-第5届疫苗创新国际论坛
    Raman Rao
    CEO, Hilleman Laboratories

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


    Genetically engineered innovative bacterial vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Rong Xu
    CSO, Delonix Bioworks, China

    Dr. Xu Rong has over 20 years of experience in innovative vaccine research and development and in leading vaccine R&D teams within multinational corporations. She particularly excels in preclinical vaccine research and evaluation, the development and validation of immunological methodologies, and the CMC development of vaccine products.

     

    Before joining Delonix, Dr. Xu held the position of Senior Vice President of Preclinical Vaccine R&D at Clover Biopharmaceuticals. Prior to that, she served as the Vice President of R&D at the Sabin Vaccine Institute in the United States, where she led the CMC development, clinical immunology assay development and validation, and non-clinical safety and efficacy studies of vaccines. Additionally, she has held several key vaccine R&D and team management roles at Profectus Biosciences, Pfizer (Wyeth), and the Seattle Biomedical Research Institute.

     

    In 2016, Dr. Xu was honored with the Distinguished Female Scientist Award by the Westchester Association in New York, recognizing her outstanding contributions to vaccine research and development. Dr. Xu holds a Bachelor degree in Medicine from Peking University and a Ph.D. in Immunology from the Weizmann Institute of Science in Israel.


    TBC
    B-cell responses in vaccinated people versus infected ones
    VIF World 2024-第5届疫苗创新国际论坛
    Fan Yang
    Professor, Shenzhen Institute of Advanced Technology, CAS
    Dr. Fan Yang, professor at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. Dr. Yang earned her Ph.D. in Molecular Genetics and Computational Biology from the University of Toronto and conducted postdoctoral research at Stanford University. Her work primarily focuses on leveraging nulti-omics techniques and big data analysis algorithms to reveal the pathogenesis of diseases such as respiratory infections and autoimmune diseases, as well as the characteristics of related adaptive immune responses. Dr. Yang has published in Science, Cell, Nature Medicine, and Cell Host & Microbe and many other top articles, totaling over 4700 citations. She also acts as a peer reviewer for journals such as Genome Research, Frontiers in Oncology, PLoS Computational Biology, and Scientific Data, and served as an editor for Frontiers in Pharmacology, a Program Committee member and reviewer for ACM Special Interest Group on Computer Science Education (SIGCSE) conferences, and a committee member of the International Workshop on Computational Mathematical Models in Cancer (CMMCA).
    Next generation pneumococcal vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    George Siber
    Adjunct Professor of Medicine, Johns Hopkins Medical School Visiting Researcher, Institute of Microbiology, Chinese Academy of Sciences President, Siber Biotechnologies LLC

    Dr. Siber is an infectious disease trained physician with more than 40 years of experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer) where he led the development and approval of multiple innovative childhood vaccines, including Prevenar 7 and 13, the first pneumococcal conjugate vaccines,  Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute and Director of the Massachusetts Public Health Biologic Laboratories where he developed multiple vaccines and immune globulins, including Respigam, the first antibody licensed for respiratory syncytial virus. Dr. Siber most recently was a Co-founder and Board Member of Affinivax which developed a 24 valent pneumococcal vaccine and was acquired by GSK in 2022. Dr. Siber currently serves on the Scientific Advisory Boards of AdVaccine, CanSino, Clover, Everest Medicines, ILiAD, Valneva, Vaxart and Vaxxinity and has been a consultant to the NIH, EU, WHO and the Gates Foundation. Dr.Siber was member of the Board of  Trustees of the International Vaccine Institute. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post‑doctoral training in Internal Medicine at Rush‑Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Boston Children’s Hospital and Beth Israel Hospital, Harvard Medical School.


    TBC
    VIF World 2024-第5届疫苗创新国际论坛
    Yao Pan
    MSAT lead, WuxiVaccine
    Dr. Yao Pan joined Wuxi Vaccine as MSAT lead and mainly responsible for process technology transfer and process validation. Before joining Wuxi Vaccine, she worked at WuXi Biologics Germany GmbH responsible for DP MSAT and project management departments. She has more than 8 years development and manufacturing experiences with vaccines, biologics as well as molecular diagnostics. Her expertise covers early development, new technology platform establishment, project management, process technology transfer and process validation. Before industrial career, she obtained her ph. D at Universität für Bodenkultur Wien and finished her post-doc at NIOO-KNAW.
    TBC
    VIF World 2024-第5届疫苗创新国际论坛
    Chongyang Liang
    Prof., Jilin University;Senior Advisor, Scientific Advisor, ProMab Forethought; Scientific Advisor, Changchun BCTH
    Professor Liang is dedicated to the development of large molecular drugs in the field of recombinant protein. He has been engaged in the research of drug action mechanism-related structural biology and physicochemical analysis for many years, leading the development of multiple innovative monoclonal antibody drugs and subunit vaccines. Through the transformation of achievements and cooperation with enterprises, he has promoted the approval of clinical trials or market launch by the US FDA and China NMPA.
    茶歇
    The thermophilic filamentous fungus, C1 - an extraordinary platform for the production of prophylactics for humans and animals
    VIF World 2024-第5届疫苗创新国际论坛
    Ronen Tchelet
    CSO, Dyadic International
    Ronen Tchelet, PhD: Ronen Tchelet joined Dyadic in May 2014 and has been Dyadic’s Vice President of Research and Business Development since January 2016 and later on became Dyadic’s CSO. Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral as an EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland. In the late 2000’s, he joined the API Division of TEVA Pharmaceutical Industries LTD., where he served as a Chief Technology Officer of Biotechnology. Dr. Tchelet leaded and directed the Research and Development Biotechnology department of TEVA’s fermentation plant in Hungary. In his work he managed and organized Biotechnology and Biosimilar projects that combined multidisciplinary areas such as development, operation, and production of API and biologics. In addition, from 2000 – 2005, Dr. Tchelet was the QA manager of COPAXONE® the flag ship TEVA¹s innovative drug. From 2007 through 2013, prior to joining Dyadic, Dr. Tchelet became the founder and the Managing Director of Codexis Laboratories Hungary kft. (CLH) and a Vice President of Codexis Inc. At CLH, he established a state-of-the-art laboratory for strain engineering and all aspects of fermentation work including process optimization and scaling up. It was during this time that Dr. Tchelet engaged with the C1 technology that was successfully developed for the Biofuel and the Bio-Industrial enzymes fields.
    Pharmaceutical Research of immunoprophylaxis for antimicrobial resistant superbug
    VIF World 2024-第5届疫苗创新国际论坛
    Quanming Zou
    Professor, Army Medical University, China
    Quanming Zou Professor & Director National Engineering Research Center of Immunological Products, Army Medical University Dr. Quanming Zou is a professor and the director of National Engineering Research Center of Immunological Products, Army Medical University. He received his PhD degree in immunology from the Third Military Medical University and research experience in University of Hannover (GER). He serves as Member of Subjects Review Group of the Academic Degrees Committee, State Council, Member of the 12th Pharmacopoeia Commission of China, Vice director of Biochemical and Biotech Medicine Professional Committee of Chinese Pharmaceutical Association, Vice director of Vaccine Research and Development Committee of the China Association for Vaccines and Vice Chairman of Chongqing Pharmaceutical Association. Dr. Zou has engaged in researches on innovative vaccines and pathogenic mechanisms and immune response of serious resistant bacteria. Prof. Zou successfully developed the Oral Recombinant Helicobacter Pylori Vaccine, which was approved with national innovative drug license. The other novel Staphylococcus Aureus Vaccine directed by Prof. Zou, have conducted the Clinical Trial phase Ⅲ. He published over 150 papers in peer-reviewed journals such as Lancet, Gastroenterology, Gut, Nature Communication,Autophagy, J Immunol, etc., and got 32 patents granted as first inventor. He won the Second prize of National Award for Technological Invention by the State Council, Outstanding Contribution to the Science and Technology Program Award by Ministry of Science and Technology, Frist prize of Chongqing Science and Technology Invention Award, Frist prize of Chongqing Natural Science Award by Chongqing Municipal People's Government, and Merit Citation Class II.
    Helicobacter pylori vaccine development
    VIF World 2024-第5届疫苗创新国际论坛
    Fan Fan
    Vice president of Chengdu Olymvax Biopharmaceuticals Inc., Head of Olymvax R&D institution
    Fan fan has nearly ten years experience in the biological industry and has made remarkable achievements. In 2016, she completed the in-licensing of Class I new drugs from Griffith University in Australia, which is the first aligned biological drugs project between universities in Queensland and enterprises in China. In June 2020, she was identified as the urgently needed talents and high-end talents by Chengdu High-tech Zone. She also serves as the standing committee member of Supply Chain Management Branch of China Association for Vaccines and the member of Meningitis Prevention and Control Branch of China Association for Vaccines. In September 2020, she was awarded the Advanced Individual against the epidemic by Sichuan Provincial Working Committee of Jiusan Society, and made her due contribution to the fight against the epidemic. In June 2021, she was awarded the Golden Panda "Talent Award" of Chengdu High-tech Zone.
    Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases
    VIF World 2024-第5届疫苗创新国际论坛
    祝先潮
    瑞宙生物CEO
    祝先潮博士:上海瑞宙生物科技有限公司创始人兼总经理,专注于创新疫苗及重组蛋白类生物制品的研发及产业化。曾在国内外一流制药企业从事新药研发二十多年,主导或参与过二十多个新型疫苗及新药研发项目,在小分子药物、重组蛋白、抗体、及疫苗产品的开发积累了丰富的经验。其中,在美国辉瑞公司圣地亚哥研发中心从事新药研发工作近13年,担任首席研究员及蛋白科学部负责人。 2011年回国后,先后在华兰生物工程股份有限公司担任首席科学官,在美国药典委员会大中华区担任生物药和生物技术部负责人和高级总监。祝博士在美国加州大学获得分子生物学及生物化学博士学位,在中科院上海有机化学研究所获得有机化学硕士学位,在清华大学获得化学系学士学位。
    Regulatory strategy to accelerate vaccine approval (TBC)
    TBC
    Reserved by 美莱德
    Evaluation on mucosal respiratory COVID -19 vaccines in clinical trials
    VIF World 2024-第5届疫苗创新国际论坛
    Jingxin Li
    Deputy Department Head, Jiangsu CDC, China

    Jingxin Li, PhD, Professor, is working at Jiangsu Provincial Center for Disease Control and Prevention. Her research is focused on vaccine clinical evaluation and immunization strategy. She has participated in a lot of epidemiology investigations and a series of clinical trials of novel vaccines, including Enterovirus type 71 vaccine, recombinant human Ad5 vectored Ebola vaccine, and Covid-19 vaccines. She has got National Natural Science Outstanding Youth Founds and Jiangsu Provincial Natural Science Funds for Distinguished youths, and hosted or participated in seven National Natural Science Founds or National Science and Technology Major Projects. She has published over 25 articles in medical journals on vaccine clinical studies, including Nature Med, Lancet Respir Med, Lancet Glob Health, etc.


    Randomized double blind Clinical Trial on Covid-19 vaccine
    VIF World 2024-第5届疫苗创新国际论坛
    Raza Shah
    Professor and Director University of Karachi, Bangladash
    Prof. Shah is working in the area of Nanomedicines and clinical trials. He has authored six books (Elsevier) and also edited four books (Elsevier), along with 12 chapters in books and more than 460 research articles in international journals with impact factor more than 1700. He has several US patents to his credit too. He has supervised and co-supervised 34 Ph.Ds. and 44 M.S/M.Phil scholars. The research projects of Dr. Shah is funded by both National and International funding agencies. He was declared top scientist for the year 2019 by the government of Pakistan. He received the Civil award Tamgha-i-Imtiaz-2015 (Medal of Distinction) from President Islamic republic of Pakistan. Atta-ur-Rahman gold medal-2006 and Dr. Raziuddin gold medal-2015 by Pakistan Academy of Sciences. He received the Abdus Salam (Nobel Laureate) award, and was selected TWAS Young Affiliate in 2010 by The World Academy of Sciences. One of his authored books was declared best book of the year 2017 by Higher Education Commission of Pakistan. He is fellow Pakistan Academy of Sciences, fellow Islamic world academy of sciences, fellow International Union of Pure and Applied Chemistry (IUPAC), fellow the Chemical Society of Pakistan and fellow Royal College of Physicians Edinburgh. He remained a member in the panel of inspectors for Evaluation of Clinical Trial Sites from Drug Regulatory Authority of Pakistan (DRAP). He conducted 28 Phase-1 clinical-trials (BE-PK) along with 04 phase-II clinical-trials for Multinational pharma as PI. He led the vaccine (COVID-19) phase-1 clinical trial of Sinopharm company in Pakistan. He led the DRAP approved clinical trial for the treatment of COVID-19 patients with traditional Chinese medicines. Various Research Projects Sponsored by International Funding Agencies such as OPCW (Organization for the Prohibition of Chemical Weapons Netherlands), COMSTEC-ISECO (Saudi Arabia), International Foundation for Science (Sweden), Third World Academy of Sciences (Italy), DTRA (USA) and European Commission National Funding like HEC and PSF
    茶歇
    TBC
    VIF World 2024-第5届疫苗创新国际论坛
    Andrew Wong
    BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, China
    Andrew Wong is Director of Business Development at Walvax Biotechnology Co., Ltd., a public listed company in China, and the general manager of its subsidiary Shanghai Wotai Biotechnology Co., Ltd.. Andrew is responsible for managing Global Registration and Sales Department and Business Development Department at Walvax. By participating in Walvax’s efforts to become a global vaccine manufacturer, between September 2015 and March 2020, Andrew managed a three collaboration projects under a combined sum of $8.5 million funding from the Bill and Melinda Gates Foundation to support the development of bivalent, nona-valent HPV vaccines and recombinant COVID-19 vaccine for developing countries. Representing Walvax, Andrew participated in the efforts with Shanghai Zerun to secure 3 grants from CEPI to support the preclinical and clinical development of the variant recombinant COVID-19 vaccines for eventual supply to COVAX. Currently, Andrew leads his teams to work on Walvax’s global business expansion through licensing-in/out and international product registration and distribution. After academic trainings from China, Canada and United States in clinical medicine, immunology, molecular biology, and business administration with an MBA from UCLA Anderson School, Andrew Wong, MD, MBA has almost three decades’ experiences in biopharmaceutical research, business development and general management, including close to 12 years’ work experience at the world’s largest biotech company - Amgen Inc. in USA, by engaging in recombinant antibody therapeutics and anticancer small molecule drug research and development.
    Driving R&D towards global public health and health equity for Vaccine: RIGHT foundation’s approach
    VIF World 2024-第5届疫苗创新国际论坛
    Hoon Sang Lee
    Chief Strategy Officer, RIGHT Foundation

    Dr. Hoon Sang Lee is a medical doctor and a global health expert, and currently the Chief Strategy Officer (CSO) of the RIGHT Foundation (Research Investment for Global Health Technology Foundation) and an adjunct professor at Yonsei University School of Public Health in Korea. Dr. Lee is also a member of Health Sector Advisory Committee of KOICA and a founding member of the Board for Korea Society of Global Health. Previously, he has worked as a health adviser for KOICA (Korea International Cooperation Agency) for bilateral health projects in various countries of Africa and Asia. Prior to KOICA, Dr. Lee worked as a medical officer at Korea CDC, managing national hepatitis B and measles immunization programme, and was involved in North Korea health programme for immunization support. Dr. Lee studied Economics and Public Policy at University of Chicago, received MD and PhD from Yonsei University School of Medicine and received MPH from Johns Hopkins School of Public Health.


    QS-21 for Advanced Adjuvants and its impact on modern vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Hao Wang
    CEO vuRoyal pharmaceutical company LLC
    CEO,vuRoyal pharmaceutical company LLC(葳瑞医药), USA and China Dr. Hao Wang is currently the CEO of vuRoyal Pharmaceutical. He received his Ph.D. from MIT and MPA from Harvard University. Previously, Dr. Wang served as the vice president of the largest university-related research foundation, the Research Foundation for the State University of New York, and the chief information officer of the United States' largest comprehensive university system, the State University of New York. Hao was a partner/managing director of Accenture, a global 500 company, and served as vice president of Accenture China, leading Accenture's healthcare practice in Greater China. He had also served as deputy commissioner of the New York State Office of Mental Health. A graduate from Peking University, Dr. Wang served as an adjunct professor in several leading research universities such as Columbia University, Tsinghua University, University at Albany, and Xian Jiaotong University.
    VIF World 2024-第5届疫苗创新国际论坛
    Damian Hiley
    Director, Desert King International
    Damian Hiley Product Manager for Vaccine Adjuvants, Desert King International, USA Since joining Desert King in 2012, Damian Hiley has played a crucial role in revolutionizing QS21 Vaccine adjuvants, leading to the pivotal launch of GMP QS21 in 2017. Beyond his substantial contributions to vaccine science, where his work underpins all commercially available vaccines with AS01 or Matrix M, Damian has spearheaded the company’s commitment to responsible forestry practices and the development of clonal plantations. His strategic oversight of the Pharmaceutical Exipient factory in Chile reflects his multifaceted expertise. Holding an MBA, Damian’s vision for sustainable innovation and leadership in global health advancements exemplifies his dedication to both environmental stewardship and medical progress.
    Evolution of flagellin adjuvant towards clinical application
    VIF World 2024-第5届疫苗创新国际论坛
    Joon Haeng Rhee
    Professor, Chonnam National University Medical School, South Korea
    Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.
    Interferons and inflammasomes in adjuvant induced immune responses
    VIF World 2024-第5届疫苗创新国际论坛
    Ed Lavelle
    Professor, Trinity College Dublin, Ireland
    Professor Ed Lavelle is the current Professor of Vaccine Immunology in Trinity College Dublin He was elected a member of the Royal Irish Academy (MRIA) in 2021 is currently President of ECI2024 and former President of the Irish Society for Immunology and head of the School of Biochemistry and Immunology at Trinity College Dublin, Ireland. He graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth and carried out postdoctoral research at the University of Nottingham, Rowett Research Institute, Maynooth University and Trinity College Dublin on vaccine adjuvants and immunomodulation. He was appointed at Trinity College Dublin as a lecturer in 2004, associate Professor in 2012, Professor in Immunology in 2015 and Professor of Vaccine Immunology in 2022. His research has led to the development of adjuvants suitable for inclusion in injectable and mucosal vaccines for infectious diseases and resolving their mode of action. The lab is also focused on developing therapeutic vaccines for cancer and investigating vaccine strategies that promote immunogenic cell death, leading to enhanced protective immunity.
    Mucosal adjuvants
    VIF World 2024-第5届疫苗创新国际论坛
    Elizabeth Norton
    Associate Professor,Tulane University, USA
    Dr. Elizabeth B. Norton is an immunologist with 20 years of experience in evaluating immunity, vaccines, and microbial infections. The focus of her research is on immunity, including drivers of diversity and therapeutic interventions. She has a public health and research background and is an Associate Professor in the Department of Microbiology & Immunology at Tulane University in New Orleans, Louisiana, USA. Dr. Norton began her training at the Centers for Disease Control in Atlanta, GA identifying correlates of sepsis in children and assisting in field studies in African hospitals. In her doctoral and post-doctoral programs, she evaluated innate immunomodulation and mucosal delivery techniques, the latter in the laboratory of Dr. John Clements at Tulane University. A focus of her lab’s research is using mucosal adjuvants derived from heat-labile toxin (e.g., dmLT) as a strategy to improve memory responses to vaccines. This has involved adjuvanted enterotoxigenic E. coli (ETEC), polio and tuberculosis vaccines sponsored by NIH and Gates Foundation. Recently, she is also pursuing novel dmLT adjuvant combinations for oral vaccination. The Norton lab has also pioneered a derivative intranasal adjuvant called LTA1 for Klebsiella pneumoniae, opioid, and influenza vaccines and is preparing for an NIH-sponsored clinical trial with the former. Part of this research involves correlates of protection from clinical trials with these adjuvants or licensed vaccines. Since the SARS-CoV-2 pandemic, her lab is also a key part of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) evaluating cellular and memory responses to SARS-CoV-2 or other infections and vaccinations in healthy adults or special populations.
    Advances in adjuvants, protein expression, and delivery technologies continue to give protein vaccines the edge; Advax-CpG adjuvant
    VIF World 2024-第5届疫苗创新国际论坛
    Nikolai Petrovsky
    Founder, Vaxine, Australia
    Professor Nikolai Petrovsky is a physician and vaccine researcher. He is the founder of Vaxine, an Australian biotechnology company applying novel approaches including artificial intelligence to vaccine and adjuvant development. His research has been awarded multi-million dollar contracts from the US National Institutes of Health and he has authored over 200 peer-reviewed research papers. He developed SpikoGen®, a vaccine against COVID-19 that received emergency use authorization in the Middle East in October 2021, making it the first recombinant protein vaccine against COVID-19 to achieve regulatory approval.
    茶歇
    Intranasal vaccination can build effective mucosal immunity wall against Omicron infection
    VIF World 2024-第5届疫苗创新国际论坛
    陈凌
    广州实验室研究员

    Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.

    TLR5 pathway-based mucosal adjuvant for design of subunit mucosal vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    鄢慧民
    复旦大学附属公卫中心研究员

    鄢慧民,博士,复旦大学上海市公共卫生临床中心,研究员,博士生导师。鄢博士毕业于武汉大学生物系,获学士、博士学位,并留校任教。1998-2002年在美国凯斯西保留地大学(Case Western Reserve University)医学院病理学系Research Associate,从事黏膜IgA抗病毒机制研究。2002年9月回国加盟武汉大学现代病毒学研究中心,参与武汉大学P3实验室SARS病毒科技攻关。2006年受聘中国科学院武汉病毒研究所,任研究员,学科组长(PI),组建黏膜免疫学科组。曾任研究所分子病毒研究室主任,病毒病理研究中心主任,研究所学位委员会副主任,湖北省免疫学会副理事长,湖北省微生物学会理事,中国病毒学(Virologica Sinica)杂志编委,中国国家知识产权局(State Intellectual Property Office of China)中国专利审查技术专家。他的实验室是中国病毒学国家重点实验室的成员单位。研究方向:黏膜免疫抗病毒机制及其应用。研究内容:病毒特异IgA抗体抗病毒机制,黏膜疫苗、黏膜佐剂与黏膜上皮细胞的相互作用及黏膜免疫效应,重组鞭毛素蛋白免疫识别机制及其在黏膜疫苗研发中的应用。2020年9月鄢博士受聘复旦大学上海市公共卫生临床中心,任黏膜免疫实验室PI,继续研究黏膜IgA抗病毒感染的功能,并更加关注病毒非表面和非结构成分特异IgA抗体在黏膜上皮细胞内地独特功能机制。相关研究证明了麻疹病毒(MV)非表面蛋白(基质蛋白M)、非结构蛋白(磷蛋白P)特异性IgA抗体可以在病毒感染的上皮细胞内转运过程中作用到病毒新合成的蛋白靶标,从而抑制病毒在黏膜上皮细胞内的复制。此外,他带领团队研发了基于TLR5的重组鞭毛蛋白黏膜佐,并应用于新型亚单位黏膜疫苗设计。相关研究获得鞭毛素蛋白佐剂、龋齿疫苗、RSV疫苗相关的美国专利3项、中国专利4项。这些研究得到了国家自然科学基金委、科技部的多个项目资助。


    Engineered design of mucus penetration nanoparticles for inhalable vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Bingbing Sun
    Professor, Dalian University of Technology, China
    Dr. Bingbing Sun received B.S. and M.S. in Chemical Engineering from Dalian University of Technology (DUT), and a Ph.D. in Chemical Engineering from the University of Washington. He had his postdoctoral training at the University of California's Center for Environmental Implications of Nanotechnology (UC-CEIN) at the University of California, Los Angeles (UCLA). He starts his academic career in the School of Chemical Engineering at DUT in 2016. Currently, he is a full professor and serves as the chair of the Department of Chemical Engineering at DUT. His research interest includes vaccine adjuvants, formulation, biomaterials, nano-bio interface, and immunoengineering. He serves as earlier career researchers editorial board of BMEMat.
    Innovative and High-Performing Lipids for mRNA Delivery
    VIF World 2024-第5届疫苗创新国际论坛
    陈永明
    中山大学教授
    Yongming Chen received his Ph.D. on polymer science in 1993 from Nankai University. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in University of Düsseldorf and University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013. He obtained “Distinguished Young Scholars” by National Science Foundation of China (2006). He served for Polymer, an Elsevier journal, as an Associate Editor during 2007 to 2018. He also was in Advisory Board Panel of Macromolecules and ACS Macro Letters, the ACS Publication. Professor Chen’s research interests are in the areas of biomaterials chemistry and biomaterials application in delivery of proteins and nucleic acids, specifically application in immune attenuation. He has published over 260 research articles in Science Advances, Nature Communication, Biomaterials, Nano Letters et al and obtained 10 more licenced patents. Contact: Email: chenym35@mail.sysu.edu.cn
    Synthetic lipopeptides as vaccine adjuvants
    VIF World 2024-第5届疫苗创新国际论坛
    Haibo Li
    Professor, Army Medical University, China
    Dr. Haibo Li is a professor in the National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, Army Medical University (Third Military Medical University). He obtained his PhD in biological technology from Third Military Medical University in 2013. His current research activities focus on integrating chemical synthesis and immunology to discover novel mucosal vaccine adjuvants. He developed an original strategy to rationally design novel lipopeptides as mucosal adjuvants by mimicking the active sites of the bacterial lipoproteins. Dr. Li has published over 50 peer-reviewed papers and several books and book chapters. Now he is a council member of Chongqing Pharmacological Society.
    Adjuvant& delivery technology
    A phase 1, placebo-controlled safety and immunogenicity trial evaluating a vaccine consisting of polyvalent, multi-subtype, DNA plasmids with matching adjuvanted gp120 proteins
    VIF World 2024-第5届疫苗创新国际论坛
    Shan Lu
    Emeritus Professor, University of Massachusetts Medical School, USA
    An update of vaccine development on Heptatis E
    VIF World 2024-第5届疫苗创新国际论坛
    James Wai Kuo Shih
    Senior Advisor, Xiamen Innovax Biotech, China
    James W. Shih is a senior advisor at the Innovax Biotech Inc. Xiamen, China and Professor Emeritus of the School of Public Health, Xiamen University, China since 2016. For over 10 years, he was Professor of Microbiology at the National Institute of Diagnostics and Vaccine Development in infectious diseases at the Xiamen University. He retired from the National Institutes of Health, Bethesda, USA in 2006. While at NIH, he was a senior investigator and served as the Chief of Lab Study, Infectious Disease Section and Supervisor of the Transmission Transmitted Virus Lab at the Department of Transfusion Medicine, NIH Clinical Center. Prof. Shih is a microbiologist with over 40 years of experience in the biomedical field. Most of his career is associated with the development and the understanding of hepatitis viruses and their clinical implications. He has managed active research programs in viral discovery and the development and evaluation of vaccines against hepatitis B and hepatitis C. He has extensive experience in development and clinical evaluation of serological and molecular diagnostics in infectious diseases. Currently, he is engaging in developing international collaborative projects one of them is the evaluation of hepatitis E vaccine.
    lnvestigation of virus-like structure vaccine based on technological strategy of lipid delivery
    VIF World 2024-第5届疫苗创新国际论坛
    Qihan Li
    Professor,IMBCAM, China
    Combination vaccine development
    VIF World 2024-第5届疫苗创新国际论坛
    Kutub Mahmood
    Scientific Director at PATH, USA
    Senior biotech executive professional with expertise in viral vaccines with 30yrs experience in vaccine development. Currently at PATH, leading projects for vaccines and biologics including product development strategies for compliance with GMP and/or GLP practices as applicable for national and international regulatory framework compliance (WHO, FDA, EMA,DCGI, NMPA). Experience in national regulatory approvals and for achieving WHO pre-qualification for vaccine products. Currently project lead for polio vaccines development and scaleup for OPV and IPV related work. Current and past projects at PATH includes work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. Holds national and international patents on VLP technology for influenza and RSV vaccines, and published in peer-reviewed journals. Presently serves as scientific advisory panel for companies and on several scientific panels for national and international vaccine meetings. Besides, serves as scientific reviewer for manuscripts submitted for publications in journals including Vaccine, Journal of Infectious Diseases, Emerging Infectious Diseases, and Human Vaccines & Therapeutics.
    Development of in vitro - assembled multivalent VLP vaccine for norovirus infection
    VIF World 2024-第5届疫苗创新国际论坛
    Deog-Young Choi
    CEO, InThera, South Korea
    2016.05 – Present InThera Inc. CEO 2010.01 – 2015.12 LG Life Sciences, Ltd Director of Vaccine Development & Business 2000.07– 2009.12 LG Life Sciences, Ltd. R&D Center Head of Research Team 1995.09 – 1999.12 State University of New York at Stony Brook Ph.D. in Biology
    茶歇
    Progress toward AIDS vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Feng Gao
    Professor & Director, Jinan University
    Dr. Feng Gao is a professor and director of the Institute of Molecular and Medical Virology at Jinan University. Dr. Gao has a long-standing interest in elucidating the origin, evolution and genetic variation of human and simian immunodeficiency viruses (HIV/SIV) as well as in studying gene function, pathogenesis and vaccines of HIV/SIV from the evolutionary perspective. He has published over 200 scientific research papers, including many in the top tier journals such as Cell, Nature and Science. He discovered that origin of HIV-1 in chimpanzees. He developed the consensus gene vaccine approach for induction of cross-subtype immune responses by reducing the distances between epidemic HIV-1 strains and vaccine immunogens. He also studied the coevolution of broadly neutralizing antibodies (bnAbs) and HIV-1 in the same infected host and discovered a cooperative mechanism between different bnAbs to drive maturation of the bnAb lineage. His publications have been cited over 31,000 times and his h-index is 83. Currently, his research mainly focuses on pathogenesis of viral infections, vaccines, transmission mechanisms, drug resistance, oncolytic viruses, ultra-sensitive detection and development of fetal immunity.
    Development of Nanoparticle Human Vaccines Utilizing A Proprietary IC-BEVS Platform
    VIF World 2024-第5届疫苗创新国际论坛
    Enqi Du
    GM/CSO, Nano Microgene, China
    Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice
    Developing a ‘One Health’ Nipah virus vaccine to protect animal and public health
    VIF World 2024-第5届疫苗创新国际论坛
    Simon Graham
    Professor, The Pirbright Institute, UK
    I am a veterinary immunologist with an interest in understanding mechanisms of protective immunity and its application to vaccine development. My early career focussed on parasitic diseases, I developed a natural cattle model for testing vaccines against onchocerciasis (river blindness), which provided the first proof-of-principle for vaccine-induced protection. I identified and evaluated vaccine candidate antigens from the apicomplexan parasite Theileria parva, which were designed to induce protective bovine CD8 T cell responses. More recently, my research has focussed on porcine viruses, such as classical swine fever (CSFV) and porcine reproductive and respiratory syndrome (PRRSV) viruses. I informed discussions on the use of emergency vaccination to control future CSF outbreaks by demonstrating that live attenuated CSFV prevented transmission of divergent CSFV strains after only 3 days. I showed that this rapid protection was associated with broadly reactive CD8 T cell responses, opening new avenues to develop DIVA vaccines for outbreak settings. For PRRSV, I contributed to the study of the enhanced pathogenicity of Eastern European strains, highlighting the threat these viruses pose; and contributed to vaccine development efforts through the identification of conserved T cell antigens. My current research is largely focussed on PRRSV and we are pursuing complimentary approaches to improved vaccine development. I am also leading research aimed at developing a Nipah virus vaccine for pigs and supporting COVID-19 vaccine development by using the pig as a preclinical model for assessing immunogenicity of vaccine candidates.
    The Importance of specific antibodies in the Development of VLP based vaccines
    VIF World 2024-第5届疫苗创新国际论坛
    Huichen Guo
    Professor, Lanzhou Veterinary Research Institute, China

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


    Targeting Chimeric Subunit Vaccines against Porcine Respiratory Pathogens
    VIF World 2024-第5届疫苗创新国际论坛
    Frank Chang
    CSO, Reber Genetics, China

    Dr. Frank Chia-Jung Chang obtains his Ph.D. from Life Science and Institute of Genome Science department of Taiwan Yang-Ming Medical University in 2012. He received his postdoctoral training at Molecular Biology Institute of Academia Sinica (Taiwan) and worked as visiting scholar in Frances H. Arnold’s laboratory (Nobel Prize in Chemistry winner in 2018), Chemical Engineering Department of Caltech (U.S.). He joined Reber Genetics as the supervisor of R&D Division in 2014. From 2017, Frank also works for business development and strategic layout of vaccine products (technology included).

     

    Dr. Chang has considerable expertise in virology, microbiology, reverse vaccinology and protein engineering for industrial production. His group has successfully developed novel subunit vaccines of swine PRRSV, pan-PCV, Mycoplasma, CSFV and PEDV in Reber Genetics, furthermore, also support the study of safe vector vaccine against ASF with external partners.


    茶歇
    mRNA based vaccine development for animal diseases
    VIF World 2024-第5届疫苗创新国际论坛
    Caiyi Fei
    Co-founder& VP, Therarna
    Next-Generation High-Yield Baculovirus/Insect Cell Protein Expression System—qBac® Bacmid
    VIF World 2024-第5届疫苗创新国际论坛
    Xiaodong Xu
    Prof., Northwest A&F University
    Xu Xiaodong, currently a professor and doctoral supervisor in the School of Life Sciences of Northwest A&F University, holds a master's degree in China Agricultural University and a doctor's degree in virology from the University of Reading, UK. He is mainly engaged in the research on the gene function and molecular biological mechanism of baculovirus, the optimization of baculovirus/insect cell expression system and the application and development of protein products. More than 10 domestic invention patents and 1 PCT international invention patent have been applied. In 2019, Xu Xiaodong led a team to discover prions in viruses for the first time in the world. The relevant scientific research results were published in the internationally renowned journal Nature Communications. Xu Xiaodong, as the founder of qBac® baculovirus/insect cell protein expression system, has improved the protein yield by the level of grams per liter by knocking out many genes that affect the protein yield, inserting siRNA to inhibit the apoptosis of host cells, and fine-tuning the expression level of transcription factors.
    议程下载

    最新议程下载

    VIF World 2024-第5届疫苗创新国际论坛VIF World-agenda0228.pdf


    注册报名
    活动筹备中
    售票推广中
    活动结束
    选择票
    门票名称
    单价(¥)
    截止时间
    数量
    标准票(国内疫苗企业、科研机构&政府部门
    2,580
    2024-03-23 18:00
    0
    此门票含会议通行证、会议资料及2天午餐各一份及一对一约见系统账户1个
    标准票(供应商及其它单位)
    3,580
    2024-03-22 23:55
    0
    此门票含会议通行证、会议资料及2天午餐各一份及一对一约见系统账户1个
    》3人
    1,980
    2024-03-23 12:00
    0
    此门票3张起购,含会议通行证、会议资料及2天午餐各一份及一对一约见系统账户1个
    》5人
    1,580
    2024-03-23 12:00
    0
    此门票5张起购,请联系组委会13482341046,含会议通行证、会议资料及2天午餐各一份及一对一约见系统账户1个
    》10人
    1,290
    2024-03-23 12:00
    0
    此门票10张起购,请联系组委会13482341046,含会议通行证、会议资料及2天午餐各一份及一对一约见系统账户1个

    退票说明:不支持退票

    优惠或邀请码
    票价
    0
    联系组委会

    个人二维码.png

    13482341046


    会议酒店预订:

    上海中谷小南国花园酒店

    主楼大床/双床:698元/间

    副楼大床/双床:498元/间

    点此预订

    1817532441808170.png